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ABSTRACT 
 
 
SUSAN MARIE ODUM.  Estimation of preference-based measures of health from 
disease-specific clinical outcome measures for total hip and knee arthroplasty patients.  
(Under the direction of DR. JENNIFER TROYER) 
 
 
 Transfer to utility (TTU) or mapping methodology allows researchers to estimate 
a health utility from a disease-specific measure and calculate quality adjusted life years 
for economic evaluations. The purpose of this study was to develop regression algorithms 
to map five common disease specific TJA outcome measur s to three preference-based 
health utility scores.  An online survey was completed by 438 total hip arthroplasty 
(THA) patients and 550 total knee arthroplasty patients (TKA). THA patients completed 
the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC®), Harris 
Hip Score (HHS), and the Hip Disability and Osteoarthritis Outcomes Score (HOOS). 
Knee patients completed the WOMAC®, Knee Society Score (KSS), and Knee Disability 
and Osteoarthritis Outcomes Score (KOOS). All patients completed three preference 
based questionnaires, the SF-6D, EQ-5D and HUI-3, and responses were used to 
calculate health utilities. A total of 30 THA mapping models and 30 TKA mapping 
models were developed and validated. Forecast error measures including ME, MAE, 
RMSE were defined as our prediction performance crit rion. For the THA models, the 
regression model with HOOS subscores most precisely estimated an EQ-5D health 
utility. The best performing TKA model mapped the KSS to the EQ-5D. Clinician-
researchers can input their disease specific data into these models to estimate health 
utilities to consider the cost-effectiveness of oste arthritis-related interventions relative to 
interventions for very different diseases and conditions.  
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INTRODUCTION 
 
 
 Osteoarthritis (OA) of the hip and knee is a degenrative disease that affects 
nearly 5 million people in the United States (U.S).1 When conservative treatments fail, 
total joint arthroplasty (TJA) is the gold standard treatment.1 The United States annual 
economic burden of TJA procedures ranges from approximately $3 billion to $6 billion.1 
As the economic burden of TJA is expected to increase it is important to consider the 
cost-effectiveness of current, as well as, new technology.2-5 
 Pain due to progressive osteoarthritis is a primary reason for performing a total 
joint arthroplasty.6 A primary benefit of total joint arthroplasty is restoration of function 
related to activities of daily living, as well as, recreational activities.6 Therefore, pain and 
function are primary outcomes of interest in total joint arthroplasty research. 
Furthermore, long-term and longitudinal clinical outcomes are of substantial interest to 
patients, surgeons and manufacturers of total jointimplants. When assessing clinical 
outcomes of TJA, it is common to use disease specific health-related quality of life 
(HRQOL) measures6-8 such as the Western Ontario and McMaster Universiti s 
Osteoarthritis Index (WOMAC®)9-11, Knee Society Score (KSS)12,13, Harris Hip Score 
(HHS)14, Hip Disability and Osteoarthritis Outcomes Score (HOOS)15-17 and Knee Injury 
and Osteoarthritis Outcomes Score (KOOS).17-19 Generic, preference-based measures of 
health include the EuroQol-5D (EQ-5D)20,21, the Health Utilities Index 3 (HUI-3)21 and 
the Short Form-6D (SF-6D). 22,23 Table 1 illustrates the subscales for each of these 
HRQOL instruments. Preference-based instruments allow the researcher to administer a 
multi-dimensional set of questions regarding overall health to the patient.  Based on prior 
research regarding societal preferences for the health st tes covered under the 
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combinations of questionnaire responses, algorithms can be applied to the patient 
responses to construct a measure a single health index score for each patient ranging from 
0 (death) to 1 (perfect health).24 The health index score represents one’s health status at 
that given point in time and reflects societal prefe nces for the combination of health 
attributes identified by the patient.  This link to preferences has resulted in the index 
being referred to as a health utility by economists.24 The health utility value is used to 
calculate quality adjusted life years (QALYs), which is the effectiveness measure for 
cost-effective analysis (CEA).24,25 QALYs are the amount of time spent in a health state 
multiplied by the health utility score given to tha health state. Figure 1 illustrates a 
simple example of these calculations.25 While disease specific measures are clinically 
useful, they do not provide a preference based measur  of health utility necessary for 
cost-utility analyses.  
 The purpose of this study is to develop regression algorithms using a transfer to 
utility (TTU) method to map five common disease specific TJA outcome measures to 
preference-based health utility scores derived from patient responses to three different 
multi-dimensional health measurement instruments.  The preferred regression models 
will be compared with outcomes from neural network analysis. 
Literature Review 
Health Related Quality of Life and Cost-effective Analysis 
 Conceptual Model. The World Health Organization’s (WHO) International 
Classification of Functioning, Disability and Health (ICF), is a framework for describing 
health and health-related states across a broad range of diseases and health conditions.26 
The ICF conceptual model (Figure 2) integrates medical and social aspects of health and 
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provides a global framework for defining and measuring health and disability.26 The 
premise of the model is that disability and function are the outcomes of the interaction 
between a health condition as well as environmental and personal contextual factors.26 
Functioning refers to all body functions, activities and participation, while disability is 
encompasses activity limitations and participation restrictions.26 Function is measured at 
three levels including the specific body part, the whole person and the whole person in a 
societal context.26 Environmental contextual factors include the structural characteristics 
of one’s living environment as well as the climate nd terrain of the one’s external 
environment.26 Personal factors include demographic characteristics as well as social 
support and psychological beliefs of health.26 
Cost-effective Analysis. Interest in considering the cost-effectiveness of medical 
care has been growing, as health care cost growth continues to outpace inflation in the 
U.S.  In general, cost-effective analysis (CEA) involves estimating the added costs 
associated with a new medical intervention relative to the improvements in a stated health 
objective attributable to the intervention. Cost utility analysis (CUA) is a type of cost 
effective analysis that assesses the value of an intervention with respect to quantity and 
quality of life.3,5,24 Quality-adjusted life years (QALYs) is a common, generic health 
outcome measure in a CUA that allows comparisons across all areas of healthcare 
interventions. 3,24,25 Therefore, information obtained through a CUA can be used as a tool 
to guide healthcare decisions with respect to cost and effectiveness. 3,24,25 
Calculating Health Utilities. Health utility is an i dividual’s preference value for a 
given health state or health outcome.3,24 Health utilities range from zero (death) to one 
(perfect health).3,24 The health utility is used to calculate QALYs, whic  is the amount of 
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time spent in a health state multiplied by the utility score given to that health state. 3,24,25 
Health utility measures are designed to reflect population preferences for different health 
states on a large number of health dimensions.3,24 This allows for comparisons of gains in 
health related quality of life across a variety of patient populations, diseases and 
intervention types.3,24  
Health utilities can be calculated using direct measurement and indirect 
measurement methods.3,24 Two common direct methods include the standard gamble 
approach and the time trade-off approach.3,24 The standard gamble approach involves 
presenting individuals with a choice of a compromised health state with a certain 
probability compared to one better health state and one worse health state both with an 
uncertain probability.3,24 The standard gamble approach is a classic way of measuring 
preferences in economics under conditions of uncertainty and is consistent with standard 
models of utility maximization.  For example, individuals are presented with a choice 
between a certain state of chronic knee pain compared to a treatment that has an uncertain 
outcome – it could result in perfect health or it could result in death.24 They are then 
asked to determine what probability of perfect health would make them indifferent to 
remaining in their current, certain state of chronic knee pain.24 If they decide they are 
indifferent at a 0.7 probability of perfect health and a 0.3 probability of death, the health 
utility level for an individual with chronic knee pain is 0.7.24  The time trade-off method, 
which is based on value theory, requires individuals to decide how many years of life 
they would be willing to sacrifice to avoid a certain compromised health state.3,24 For 
example, individuals are asked to contemplate how many years of life they are willing to 
sacrifice to avoid a certain health state of chronic k ee pain.  For instance, an individual 
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might be told that they have a choice between ten additional years of life with chronic 
knee pain or a shorter lifetime without chronic knee painIf one is indifferent between ten 
years of chronic knee pain and seven years without chronic knee pain, the utility level for 
an individual with chronic knee pain is 0.7.24 There is no psychometric evidence 
suggesting that individuals make health care decisions n this precise way. However, 
individuals often make choices where they trade off a lower-valued but certain payoff for 
a higher but uncertain expected payoff (standard gamble); in addition, individuals 
indicate a willingness to trade off time for increas d health.  The standard gamble and the 
time trade-off are two methods that direct people’s attention and force them to decide 
between the presented options. Because people are inherently risk averse, the standard 
gamble tends to yield higher utility values than the ime trade-off method. In other words 
individuals will choose a higher probability value of perfect health to avoid a higher 
probability of death.24,27 
Generic, preference-based instruments, such as the EQ-5D, measure health utility 
using an indirect method.24 Each generic, preference-based instrument includes a variety 
of attributes that are valued by large population samples using direct measurement 
methods such as the standard gamble approach.24 Finally, a scoring algorithm is 
developed to generate unique weighted health states.24 When disease specific measures 
have been collected and are available but generic preference-based measures are not 
available, a mathematical technique called transfer to utility, or mapping, is an option to 
obtain a health utility when needed for a CUA.  
Cost Utility Analysis and Total Joint Arthroplasty. Total joint arthroplasty is the 
most widely studied orthopedic surgical procedure.3,4 This field has experienced 
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tremendous growth with substantial advances in medical technology and total joint 
implant design.3,4 While the efficacy and effectiveness research is important for clinical 
decision making, economic evaluations, such as cost utility analysis, are paramount in 
determining the true societal value of such advances.3,4 A well designed cost utility 
analysis requires a societal perspective, accurate tility measures, discounting of health 
costs and accurate medical costs.3,4 The associated medical costs should encompass all 
indirect medical costs, direct medical costs, opportunity costs and projected medical 
costs.3,4  
In a 2004 review of cost-utility analysis, Bozic et al.4 reported that of the 116 
cost-utility analyses published between 1976 and 2001, only 37 were orthopedic related. 
Of the 37 orthopedic related CUAs, 11 were associated with total joint arthroplasty.4 All 
of the TJA studies reported that the procedure was cost-effective with ratios below the 
threshold value of $50,000 per QALY.4 However, the methodological quality of these 
studies was inconsistent and poor.4 For example, the source of the health utility could not 
be determined in 24%.4  
Economic evaluation in orthopedics is in its infancy as illustrated by inadequately 
designed studies.3,4 Transfer to utility offers clinicians a practical and immediate method 
of assessing the cost-effectiveness of various total joint interventions and technological 
advances. For clinicians that collect disease specific measures to evaluate long-term and 
longitudinal outcomes, the regression algorithms can be used to map the disease specific 
scores to a health utility measure. The resulting healt  utilities can then be used to 
construct QALYs which are then used to calculate the incremental cost-effective ratio to 
evaluate the benefits gained from new interventions and technology. Ultimately, the cost-
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effectiveness information can facilitate clinical and policy decision making when 
considering the adoption of new health care interventions. For example, a new total joint 
implant that potentially provides improved performance and longevity is approved for 
marketing. This new implant may differ in design from an older, yet similar, implant that 
the surgeon used previously. Disease specific measur s can be used to compare the safety 
and efficacy of the two implants. The surgeon can further evaluate the cost effectiveness 
of these two implants using the TTU regression models. Based on the QALYs gained and 
the cost differential between the two implants, the decision can be made to utilize the 
most cost-effective implant.  
Total Joint Arthroplasty Health Related Quality of Life Measures 
Disease Specific Measures  
 Over the past few decades, several disease specific measures have been used to 
evaluate outcomes following TJA and there has been wide variation in the reporting of 
these measures.6,7,28 Such variation introduces challenges in comparing the literature, 
which has clinical decision making, research and policy implications. Riddle et al.28 
conducted a meta-analysis to determine the extent of the variation in the use of such 
measurement tools implemented in randomized clinica trials.28 The findings indicate that 
the KSS and WOMAC® instruments are the most commonly reported primary outcome 
for knee arthroplasty and the HHS and WOMAC® are the most commonly used tools to 
assess outcomes of hip arthroplasty.28 Similarly, Ethgen et al.8 reported that the  
WOMAC® was the most commonly reported instrument in cohort studies of TJA but this 
review did not include HHS or KSS in the criteria.  
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 Harris Hip Score. The HHS was developed in 1968 by an orthopedic surgeon, 
William H. Harris.14,29 The HHS includes pain, function, range of motion and hip 
deformity constructs.14,29  Both patient-reported and provider-reported measures are 
included and the maximum score is 100 points.14,29 Higher scores represent better clinical 
outcomes.14 Of the total 100 possible points, 44 possible points are allocated for pain and 
47 points are allocated for function.14 The remaining points are assigned to range of 
motion and absence of deformity.14 While the Harris Hip Score was initially tested on a 
small series of 38 hip fracture cases, it was also designed to be used with a variety of  hip 
conditions and treatment options.14 
 Knee Society Score. The KSS was initially developed by the Knee Society in 
1989 and further modified in 1993.12 Based on a panel of surgical and clinical experts, 
i.e., Knee Society members, three main constructs were included in the score: pain, knee 
joint stability, and range of motion.12  Similar to the HHS scoring algorithm, the 
maximum score is 100 points with higher scores indicating better clinical outcomes. Of 
the 100 points, a possible 50 points are assigned to pain, 25 points are for stability and 25 
points are possible for range of motion.12 Deformity and misalignment of the native joint 
and the knee arthroplasty are assessed but are deductions in the overall score.12 A well-
aligned knee with no pain, 125 degrees of motion, and good anteroposterior and 
mediolateral instability will achieve a KSS of 100 points.12 The maximum function score 
is also 100 points and consists of patient reported outcomes that measure walking 
distance (50 points) and the ability to ascend and descend stairs (50 points).12 The use of 
assistive walking devices, such as canes and walkers, are deducted from the total function 
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score.12 It is common in the TKA literature to report the pain score, the function score as 
well as the total score. 
 Western Ontario-McMaster Osteoarthritis Index. The WOMAC® was developed 
in 1982 as a patient reported measure of hip and knee osteoarthritis.9-11 The WOMAC® 
consists of 24 questions assessing three dimensions of pain, disability, and joint 
stiffness.9-11 Because OA patients and physicians were involved in the development of 
the questionnaire, the items represent aspects of OA that are relevant to both.9-11 Through 
numerous validation studies, it has been shown to be valid, reliable and responsive across 
a number of interventions.9-11,13 The KOOS was developed in 1998 to assess clinical 
outcomes related to a variety of treatments for knee i juries as well as osteoarthritis.17-19 
The KOOS is a patient reported clinical outcome measure designed to evaluate clinical 
change over time. 17-19 The questionnaire includes all WOMAC® questions in their 
original form as well as questions related to sports and recreational specific activity 
related difficulties and knee related health related quality of life. 17-19 Subsequently, the 
HOOS was developed as an analogous clinical measure for hip related conditions. 15-17 
Several studies have shown that the HOOS and KOOS are valid, reliable and responsive 
measures across a number of interventions.17-19   
A literature search revealed that population values for the disease specific 
measures are not reported. The reported literature is specific to single studies. While 
institutions may prospectively collect disease specific measures to evaluate clinical 
outcomes of treatments there is currently no nationl repository of total joint clinical 
outcome data using disease specific or generic, preference-based measures.  
Generic, Preference Based Measures 
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 Generic, preference-based HRQOL instruments provide an indirect measure of 
generic health utility. The EQ-5D20,21, HUI-321,30 and SF-6D31 are three commonly 
reported generic, preference based HRQOL measures. Th e instruments include a set of 
non-disease-specific health states that are based on a c mbination of general attributes 
that have been valued by a sample of the general population. A scoring algorithm is 
created and patients with any disease complete the questionnaire and the appropriate 
scoring algorithm is applied to define the generic health state. The calculated single 
utility score is on an interval measurement scale, r nging from 0 to 1.  
 Health Utilities Index-3. The HUI-3 consists of eight structurally independent 
attributes: vision, hearing, speech, ambulation, dexterity, emotion, cognition and pain.21,30 
The HUI-3 defines 972,000 unique health states. 21,30 The HUI-3 score is based on 
community preferences developed using a visual analog scale and a standard gamble 
approach.21,30 The utility score is derived using a multiplicative, multi-attribute 
mathematical utility function. 21,30 The multiplicative algorithm defines the interactions 
among various health states and accurately predicts average scores for independent 
samples with a variety of diseases.21,30 Several studies have tested the reliability and 
validity of the HUI-3 across diverse populations and a variety of disease conditions and 
intervention types.21,30 
 EuroQol 5D. The EQ-5D includes five attributes: mobility, self-care, usual 
activity, pain and discomfort, and anxiety and depression. 20,21 The permutations of the 
five attributes result in 243 unique health states. 20,21 Preference weights were developed 
using valuation population sets based on the visual an log scale technique and the time 
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trade-off method (TTO). 20,21 The EQ-5D utility score is calculated using a scoring 
algorithm that is based on econometric modeling. 20,21 
 Short Form 12 and Short Form 6D. The SF-12 is a 12item self-reported 
questionnaire that includes fewer questions of the eight attributes included in the original 
SF-36.31 The eight attributes are as follows: physical functioning, role physical, role 
emotional, social functioning, bodily pain, mental health, and vitality.31 Using the Quality 
Metric scoring services, SF-12 responses are converted to the SF-6D health utility 
score.31 The SF-6D combines the role physical and role emotional attributes into one 
attribute defined as role participation.22,23,31 The SF-6D uses an econometric scoring 
algorithm with population based preference weights.22,23 In developing the algorithm, a 
total of 18,000 unique health states were defined using the standard gamble method.22,23 
 Comparative Utility Studies. Because the EQ-5D, HUI-3 and SF-6D have been 
shown to generate different utilities based on the condition and population, it is important 
that the appropriate instrument is selected.32,33 Barton et al.32 compared the scores from 
the EQ-5D and the SF-6D to measure the benefits allevi ting knee pain. The study 
findings showed that both scores had comparable construct validity.32 However, the SF-
6D did not discriminate between those who improved post intervention and those who 
showed no improvement.32 Blanchard et al.33 investigated the construct validity of the 
HUI-3 in a series of patients with OA of the hip awaiting hip arthroplasty. One hundred 
and fourteen patients completed the HUI-3, HHS, and WOMAC® questionnaires. 33 The 
mobility and ambulation attributes of the HUI-3 showed moderate correlations with the 
HHS total score, and the physical function attribute of the WOMAC®.33 The HUI-3 pain 
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attribute indicated a strong correlation with the WOMAC® physical function as well as 
moderate correlations with the HHS pain score and the WOMAC® pain score.33   
Transfer to Utility 
 Transfer to utility is recognized as a valid method of obtaining a health utility to 
calculate QALYs for economic evaluations. There are two common types of TTU. One 
method, which is not the type being considered in the dissertation, involves mapping a 
generic (general health), non-preference based measure, such as Short Form 36 to a 
generic, preference-based measure, such as the Short Form 6-D. The second type of TTU, 
which is the type being considered in the dissertation, is to map a disease specific, non-
preference based measure, such as the KOOS to the preference-based EQ-5D. To conduct 
a TTU, two data sets are required to develop the regression model. First, the estimation 
data set is initially used to develop the regression m del. Once the best model is selected, 
it is then tested on the second data set to estimate the health utility from the disease 
specific measure. In a review of mapping studies, Brazier et al. included 38 papers that 
either mapped generic non-preference-based measures or disease specific measures to a 
generic preference based-measure. A total of 119 models were used across these 38 
papers and the EQ-5D was the most common generic prference based-measure used. 
The sample sizes ranged from 68 to over 23,000 participants. A total of 12 studies were 
reviewed that used a disease specific measure and four of these were unpublished 
manuscripts or conference proceedings.  
 Transfer to utility has been utilized to predict health utilities from disease specific, 
non-preference based measures for several healthcare populations and disease conditions, 
including stroke34, obesity35, oral health36, hydrocephalus37, angina38, and arthritis39,40. 
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Two studies assessing stroke and obesity are describ d in more detail to illustrate the 
large variation in the precision of regression models in estimating health utilities from 
disease specific measures. Mortimer et al. developed regression models to estimate 
preference-based scores using the Assessment of Quality of Life (AQoL) from the 
disease specific National Institutes of Stroke Scale. The authors found a significant 
difference between the observed and estimated AQoL utility scores with mean absolute 
errors that ranged from 0.12 to 0.31 depending on the severity of the disability. Brazier et 
al assessed the accuracy of TTU regression models in stimating the SF-6D utility from 
the Impact of Weight on Quality of Life-Lite (IWQOL-lite) in a study sample of obese 
patients. The mean absolute error between the observed and the estimated SF-6D scores 
was only 0.098.  
While the use of TTU to map values from disease specific health measurement 
instruments to utilities derived from generic health measurement instruments is 
increasing there have been few studies related to OA and TJA.32,39-42 Furthermore, the 
WOMAC® is the only disease specific instrument that has been mapped to predict a 
preference-based health utility. Grootendorst et al.39 constructed regression models to 
estimate health utility using the HUI-3 from the WOMAC® subscale scores in 255 knee 
arthroplasty patients. The best performing regression model included the WOMAC® 
subscales, the squared and interaction terms of the WOMAC® subscales as well as age, 
gender and duration of symptoms. The root mean squared error (RMSE) was 0.2065.39 In 
a similar study, Marshall et al.40 used the Grootendorst et al.39 model in 145 preoperative 
hip patients and reported a RMSE of 0.1698.40  
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 A TTU model to predict a health utility derived from the EQ-5D using elements 
of the WOMAC® instrument was developed using a sample of 348 patients with knee 
pain.32 Barton et al. reported a RMSE of 0.180.32 The authors also compared the QALYs 
calculated using the observed utility scores to the estimated utility scores and found that 
the calculated QALYs using the predicted health utilities were lower compared to the 
actual utility scores.32  
In a review of mapping literature, Mortimer et al.41 addressed the methodological 
and conceptual concerns with TTU regression and found large variation in the 
explanatory power of regression models. A broad overview of study results indicate that 
the explanatory power of models mapping disease specific HRQOL scores, such as the 
WOMAC®, is generally lower when compared to other models mapping broader 
HRQOL scores, such as the SF-36.41 Mortimer cautions that disease specific instruments 
that are designed to measure detailed, or narrow, cnstructs may not be appropriate for 
TTU to a broader utility measure that covers a broad array of constructs.41 The addition 
of data that captures a broader clinical picture may i prove the models’ ability to 
estimate health utilities.41  
 Mortimer et al.41 addressed additional methodological concerns with the TTU 
regression method that remain unanswered in the curr nt body of knowledge and should 
be considered. First, a series of group specific mappings for different conditions and 
severities may provide weaker utility predictive power than a single population based 
mapping.41 Second, many disease specific instruments generate ordinal level scores 
which are then mapped to an interval level utility score.41 Such models may compromise 
the ability of the predicted utility to maintain equal proportion changes in the calculated 
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QALY. 41 The extent to which one score maps to another is large y an empirical issue 
that has been understudied for instruments commonly administered in an orthopedic 
setting. 
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METHODS 
 
 
Design and Data Source 
 This study was reviewed and approved as an expedited protocol by the Carolinas 
HealthCare System Institutional Review Board, the University of North Carolina at 
Charlotte Institutional Review Board and the Porter and Littleton Adventist Hospital 
Joint Institutional Review Board. Informed consent was waived. Potential participants 
were presented with a study overview and request for volunteer participation (See 
Appendix 2). Survey responses were stored in the password protected, 21 CFR Part 11 
compliant, patient registry.  
The data obtained from this cross-sectional survey of postoperative total hip and 
total knee arthroplasty patients who had surgery at either OrthoCarolina, P.A. (OC) 
located in Charlotte N.C or Colorado Joint Replacement Center (CJR) located in Denver, 
C.O.. The data obtained from this survey were used to develop regression equations using 
the TTU method to map disease specific outcome measur s to generic, preference-based 
health utility scores. Participants were identified and recruited using the OrthoCarolina, 
P.A. Patient Registry and the Colorado Joint Replacement Center Patient Registry, which 
both store longitudinal data for TJA procedures.  
The OC Hip and Knee Center and the CJR are both private, tertiary practices of 
specialty hip and knee replacement surgeons located in metropolitan areas. Eight hip and 
knee replacement surgeons practice at OC and five surgeons at CJR specialize in hip and 
knee replacement. On an annual basis, approximately 2,600 total joint surgeries are 
performed at OC and approximately 1,300 are performed at CJR. While the majority of 
patients reside in-state, approximately 15% travel from adjoining states and 3% from 
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other regions. These proportions are similar between each practice. Additionally, the 
payer mix at each practice is similar. Among the CJR total joint patient population, a total 
of 41% are Medicare beneficiaries, 54% have private insurance, and 5% are Medicaid. 
The proportion of OC patients with Medicare is slightly higher at 51%. The proportion of 
OC patients with private insurance is approximately 46% and the remaining 3% are 
Medicaid, self pay or workers compensation. 
 Both centers use the same registry software which has the technological capability 
to send a secure email to individuals with email addresses on file. Those who volunteered 
participation were presented with a link to the online survey and provided a general study 
overview and the specific instructions that accompany each questionnaire. Individuals 
who had any type of total hip replacement were asked to complete the HHS, WOMAC®, 
and HOOS disease specific questionnaires. Individuals who had any type of total knee 
replacement were asked to complete the KSS, WOMAC® and KOOS disease specific 
questionnaires. For patients who have had more than one joint replacement, the most 
recent was included in the sample. All patients were asked to complete the EQ-5D, SF-12 
and HUI-3 generic, preference based health utility questionnaires. The HOOS and KOOS 
questions contain all of the WOMAC® questions and individuals were only asked those 
questions one time. Additionally, only the patient-reported pain and function constructs 
of the KSS and HHS were asked. The total number of questions was 47 for hip patients 
and 48 for knee patients and it was estimated to take 30 minutes to complete.  To 
maximize response rate, three email blasts were sent. B tween February 2011 and April 
2011, three emails were sent to each OC TJA patient. The CJRI patients were each sent 
three emails between June 2011 and August 2011. Due to th  programming of the online 
18 
 
survey, it was not possible for participants to submit responses more than one time. To 
minimize any order effects, patients from the study sample were randomly assigned to 
one of six blocks, which defined a different order of clinical measures and utility 
measures. The blocks are presented in Table 2. 
 A total of 1,788 total hip replacement patients and 2,458 total knee replacement 
patients were sent an email. Of the 4,246 emails sent, 3,258 (76.7%) patients did not 
complete the survey. The reasons for non-responses are as follows: 13 declined 
participation; 116 initiated the survey but did notanswer any questions; 110 email 
addresses were identified as invalid; and 3,019 patients did not respond in any manner. 
Therefore, 988 (23.3%) patients were willing to participate. The 110 invalid email 
addresses were entered into the registry as @none.com or @decline.com and discovered 
at the time of analysis. It is not possible to determine how many of the 3,019 
nonresponders had invalid emails due to either an in ctive email account or a misspelled 
address. Therefore, the 23.3% response rate may be underestimated.  
A total of 438 total hip replacement patients and 550 total knee patients 
participated in the survey. The total number of completed sets of the five disease specific 
TJA outcome measures and each of the three preference-based health measures is 
presented in Table 3. Of the 988 total joint replacement patients included in the sample, 
504 were female, 484 were male and the average age w s 61.0 years (SD 9.8 years).  
To determine any differences between patients with respect to having an email 
address, 2,789 patients who had an email address on file (emailers) were compared to 
2,370 patients who did not have a documented email address (nonemailers). Due to 
HIPAA issues, only data from the OrthoCarolina, P.A. Registry was available to assess 
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any differences between emailers and nonemailers. Therefore, the sample of nonemailers 
was obtained from a query of OrthoCarolina, P.A. registry patients who had a 
postoperative evaluation between January 2010 and December 2011. The emailers 
sample included only OrthoCarolina, P.A. study patients to minimize any further bias 
between sites. A significantly (p=0.0002) greater proportion of patients with no known 
email address were females. Of the 2,370 patients without a known email address, 1407 
(59%) were females and 963 (41%) were males. Patients with no email address were 
significantly (p<0.0001) older than those with an email address. The average age of 
patients with no email address was 64.5 years (SD 11.8 years) compared to 61 years (SD 
11.0 years) for the group of patients with a documented email address.    
To determine any differences between patients who responded to the survey and 
those that did not respond, the 3,128 nonresponders were compared to the 988 responders 
with respect to gender, age and time since surgery. A significantly (p=0.036) greater 
proportion of nonresponders were females. Of the 3,128 nonresponders, 1715 (55%) were 
females and 1,413 (45%) were males. The mean age of nonresponders was 61.2 years 
(SD 11.2 years) compared to 61.0 years (SD 9.8 years) for responders (p=.62). There was 
also no significant (p=0.95) difference in the time since surgery between the two groups. 
The average time since surgery for both groups was 50 months. 
Analysis Plan 
 Sample Size Estimate 
Gatsonis and Sampson developed mathematical formulas to estimate power and 
sample size estimates for use in observational studies in which the independent variables 
are not fixed but are the outcome study measures.43 The proposed regression models will 
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find significant beta coefficients ranging from 0.15 to 0.20 based on the following inputs: 
1) available sample size; 2) number of independent variables in the model; 3) alpha level 
of 0.05; and 5) 80% power.43 The available sample size ranges from 399 to 506 (sample 
sizes can be found in Table 3) based on the number of completed responses on each pair 
of disease specific measure and preference-based measure. Depending on the regression 
model, the number of independent variables ranges from 4 to 23. The number of 
independent variables for each regression model can be found in Table 4. Individual 
power estimates were derived for each combination of i put possibilities.  These 
estimates resulted in a range of 0.15 to 0.20 beta coefficients that will result in statistical 
significance at an alpha level of 0.05. 
Univariate Analysis and Bivariate Analysis 
Descriptive statistics of the sample demographics and scores for all questionnaires 
were calculated. These data were used to compare results to previous TJA research to 
determine generalizability of the findings. As discu sed above, bivariate analyses were 
used to determine any differences between those who responded (responders) to the 
survey and those who did not respond to the survey (nonresponders). Additionally, 
bivariate analyses were used to determine any differences in those patients who had email 
addresses (emailers) on file and those that did not have email addresses (nonemailers) on 
file. The Wilks-Shapiro test was used to determine normal distribution of the residuals. 
Differences in proportions of each gender were assessed using a Chi Square test. . For 
normally distributed data, the differences in means between two groups were assessed 
using a Student t-test. A one-way analysis of variance (ANOVA) was used to determine 
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differences in the means between more than two groups. For data that was not normally 
distributed, a Wilcoxon two-sample test and Kruskal-Wallis test were used.  
In the absence of an accepted threshold for clinicaly significant differences in the 
disease-specific measures and health utilities, an expert panel of adult reconstruction 
surgeons from OC was convened and polled.  The HOOS, K OS and WOMAC are 
measured using a five-point Likert scale and scored from 0 (worst) to 100 (best). The 
panel recommended that scores within ten points or a 10 percentage point difference 
between groups is not clinically meaningful.   
Development of Prediction Models 
As noted above, the key objective was to develop models that allow for the 
prediction of non-disease specific utility values from commonly used osteoarthritis-
specific measures of pain and functioning.  For each osteoarthritis-specific measure, a set 
of linear regression models were estimated for each of t e three derived utility values 
indicating overall health using various functions of the survey elements from the 
osteoarthritis-specific measurement tool, demographic variables (age, gender), and time 
since surgery (years).  For instance, using responses from the WOMAC®, which include 
a composite score (totalWOMAC®) and subscales for the degree of pain (pain), mobility 
(mobility), and stiffness (stiffness), the following models of utility as derived from the 
EQ-5D (utility1) were estimated: 
1) Utility = β0 + β1totalWOMAC
® + β2age + β3gender + β4years + µ 
2) Utility = β0 + β1pain + β2mobility + β3stiffness + β4age + β5gender + β6years + 
µ 
3) Utility = β0 + β1totalWOMAC
® + β2age + β3gender + β4years + 
β5totalWOMAC
®*age + β6totalWOMAC
®*gender + β7totalWOMAC
®*years + 
β8totalWOMAC
®2 + β9age
2 + β10years
2 + µ 
4) Utility = β0 + β1pain + β2mobility + β3stiffness + β4age + β5gender + β6years + 
β7pain*age + β8pain*gender + β9pain*years + β10mobility*age + 
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β11mobility*gender + β12mobility*years + β13stiffness*age + β14stiffness*gender 
+ β15stiffness*years + β16pain
2 + β17mobility
2
 +  β18stiffness
2 + β19age
2 + 
β20years
2+ µ 
 
Regression models for the KSS/HHS and KOOS/HOOS instruments are shown in 
Table 3.  Prediction models were constructed using 85% of the data for model 
development (in-sample), and 15% of the sample was held back and used only for 
assessing the predictive ability of the models with a sample not used to estimate the 
models (out-of-sample).  Models were estimated using ordinary least squares.  Prediction 
performance of the models was assessed using both in-sample and out-of-sample 
measures of prediction performance.  Figure 3 illustrates a schema of the analytical steps 
involved in the mapping. The primary criterion used to assess model performance was the 
mean absolute error (the average absolute prediction err r), where the preferred model 
will have the lowest mean absolute error.  In addition, all models were evaluated using 
the mean error, the root mean squared error (the positive square root of the average 
squared prediction error) and the proportion of observations with absolute prediction 
errors above 0.1 for each model.  Because there is no consensus in the literature for an 
acceptable proportion of observations with a large (>.1) absolute predication error, a 
determination was made that models with 10% or more of the forecast errors greater than 
0.1 were not acceptable for individual prediction. Therefore, if 10%, or less of the 
forecast error was greater than 0.1, the model is deemed appropriate for use in estimating 
health utility values at the individual observation level in this study.  
For each osteoarthritis-specific measure of pain and fu ctioning, a formula was 
derived to estimate each of the three overall utility scores based on each osteoarthritis-
specific measurement tool, demographic variables, and time since surgery.  These 
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formulas were programmed into a basic SAS program to share with future researchers. In 
addition to the regression models previously described, neural networks (NN) were used 
to estimate each heath utility measure from each disease specific measure for each of the 
best performing regression models. A neural network is a computational data modeling 
method that is more precise and robust in handling complex, nonlinear data.44,45 This 
method has been used in a variety of scientific areas such as medicine, economics, and 
sociology.44,45 In general, NNs are modeled to simulate the processes of the human 
brain.44,45 The initial layer of computational nodes represent the model inputs, such as 
the disease specific data.44,45 These nodes are weighted and a mathematical function is 
modeled to estimate the output nodes, which in this case is the health utility.44,45 The 
general design of the neural network is diagramed in Figure 4. Similar to the mapping 
process a sample of the data is used to train the NN.44,45 This training process is an 
iterative process that compares the error in the estimated output and adjusts the weights to 
improve the accuracy of the NN.44,45 Once the NN reaches the minimal error calculation, 
the training process is complete and the NN design i  fi alized.44,45 The remaining data is 
then input into the NN and the final model estimates the health utility.44,45 The mean 
absolute error and the root mean square error of the NN’s were compared to the best 
performing linear regression model to determine the most accurate method of estimating 
the health utility from the disease specific measure. While a NN with three hidden nodes 
was used for analysis, additional networks were tested by varying the number of hidden 
nodes until it was clear that the MAE and RMSE were increasing.  
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RESULTS 
 
 
Total Hip Arthroplasty  
Results of Univariate Analysis 
Sample Characteristics. Of the 987 individuals who participated in the online 
survey, 437 (44.3%) were THA patients. The majority of the THA patients were female 
(Table 5) and the mean age of the THA patients was 62.97 years (SD 10.75 years; Range 
23.87 – 95.45 years). More than half of THA patients were < 65 years old (242 of 437 
(55.4%)), 147 (33.6%) were between 65 years and 75 years old and only 48 (11%) were 
over the age of 75 years (Table 5). The mean follow-up for the THA cohort was 3.6 years 
(SD 3.63 years). One hundred and eighty one (41.4%) of the THA patients were less than 
two years from surgery, 155 (35.5%) patients were btween two years and five years 
from surgery and 101 (23.1%) had greater than five years follow-up.  
The demographics of the THA patients included in the study sample were similar 
to the THA patient population at OrthoCarolina. The m an age of the hip patients in the 
study sample was 62.97 years (SD 10.75 years) and the mean age for OC hip patients was 
62.87 years (SD 12.65 years). This difference was not statistically significant (p=0.88). 
However, a significantly (P<0.0001) lower proportion f hip patients in the study sample 
were greater than 75 years of age (11%) than in the OC THA patient population (17%). 
There was a greater proportion of female THA patients at OC (53%) as compared to the 
hip patients included in the study (49%).  This difference was not statistically significant 
(p=0.13). 
Disease Specific Measures. Out of a maximum score of 44 points, which indicates 
no pain, the mean HHS pain score was 36 points (SD 9.9 points; Range 0 – 44 points). In 
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this cohort of THA patients, the mean HHS function score was 40.8 (SD 14.0 points; 
Range 0 - 47 points) out of a maximum HHS function score of 47 points. The total 
WOMAC® score is a composite of the function, pain and stiffness subscores. The mean 
score of 78 points (SD 22.3 points; Range 0 – 100 points) for the domain of stiffness was 
the lowest subscore. Pain and function were 83 points (SD 19.2 points; Range 0 – 100 
points) and 81 points (SD 19.1 points; Range 0 – 100 points), respectively. The mean 
total WOMAC® score for THA patients was 81 (SD 19.1; Range 0 – 1 0 points). The 
HOOS score includes subscores for activity of daily living function (FnADL), sports and 
recreation activity function (FnSRA), pain, quality of life (QOL), and knee symptoms. 
While the HOOS questionnaire includes the total WOMAC® score, there is no total 
HOOS score. Patients rated themselves the lowest with respect to FnSRA (Mean 69 
points; SD 26.2 points; Range 0 – 100 points) and QOL (Mean 73 points; SD 23.4 points; 
Range 0 – 100 points). The HOOS pain subscore, FnADL subscore, and symptom 
subscore were all between 81 points and 83 points, o  average.  
Generic, Preference-based Measures. Table 6 illustrate  the median values for all 
three health utility measures. The health utility values derived from the SF-6D were 
slightly lower (Median 0.86 points; IQR 0.26; Range 0.37 – 1.00) on average than the 
values derived from the HUI-3 and slightly higher than the EQ-5D. The median EQ-5D 
value was 0.84 points ( IQR 0.20; Range ) The median value of 0.91 (IQR 0.19; Range 
0.08 – 1.00) points obtained from the HUI-3 was the highest median health utility value.  
Results of Bivariate Analysis 
Sample Characteristics. A Student T-test was used to determine differences 
between the mean disease specific scores and between mal s and females.  Using a 
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standard significance level of 5%, there were no significant differences between males 
and females in age at the time of follow-up, time since surgery, or pain and function 
levels.  Table 7 illustrates the differences with respect to gender.  
Analysis of variance tests were used to compare the mean values of the disease 
specific measures with respect to the three age groups (Table 8) and three follow-up 
periods (Table 9). As indicated by lower Harris Hip pain scores, average pain levels were 
significantly (p=0.0004) higher among patients who were less than 65 years of age as 
compared to those patients in either of the older ag  groups. While there are no criteria 
defined for clinically meaningful differences in the HHS subscores, there are categories 
of pain scores. Therefore, we defined a clinically meaningful difference as average scores 
that are defined by different categories. Mild pain is defined as a score ranging from 30 to 
39. Therefore, the statistically significant difference in HHS pain subscores between age-
groups does not represent a clinically meaningful di ference.    
While there were no significant differences in HHS function scores, the modified 
total HHS scores were significantly (p=0.01) lower among the youngest patients.  
Because there are no defined categories of the modified total HHS, we used a threshold 
value of 10 points to define clinical relevance. Thus, we do not denote the statistically 
significant difference in the modified total HHS as a clinically meaningful difference. As 
measured by each domain of the WOMAC® and HOOS questionnaires, patients in the 
youngest age group experience more postoperative pan and decreased function as 
compared to patients who are greater than 65 years of ge at the time of survey. These 
differences are statistically significant for WOMAC® pain (p=0.04), WOMAC® stiffness 
(p=0.05), HOOS pain (p=0.02), HOOS QOL (p<0.0001), HOOS Symptoms (p=0.01). In 
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each of these subscores, the largest differences were noted between patients less than 65 
years old and those greater than 75 years old. There ar  no formal criteria for interpreting 
whether these differences in the WOMAC® subscores and HOOS subscores are clinically 
meaningful. Both of these measures are based on a 5-point Likert scale with scores 
ranging from 0 (worst) to 100 (best). With that in mind, we posit that any differences in 
WOMAC® hip scores and HOOS scores that were within ten poi ts are not clinically 
significant. Therefore, the differences in all of WOMAC® hip subscores, between age 
groups are not clinically meaningful. Similarly, the only clinically meaningful age-group 
difference was noted with the HOOS QOL subscore.  
Patients who were less than two years from surgery at the time of the survey have 
higher postoperative pain levels and lower postoperative function levels as compared to 
those who are either between two and five years or greater than five years from surgery. 
These differences were statistically significant for the HHS pain (p=0.03), HHS function 
(p=0.05) and HHS modified total (p=0.02) scores as well as WOMAC® stiffness (p=0.02) 
and HOOS FnSRA (p=0.01). As previously described, we defined a clinically meaningful 
difference using a threshold of a ten point differenc  in the WOMAC® hip subscores and 
the HOOS subscores. Therefore, we do not consider any of the above statistically 
significant differences between followup intervals clinically meaningful.  
Generic, Preference-based Measures. Wilcoxon two-sample tests and Kruskal-
Wallis tests were used to determine statistical differences in health utilities with respect 
to gender, age-group, and time since surgery. There w  no significant differences 
between males and females in the SF-6D (p=0.87), the EQ-5D (p=.84) or the HUI-3 
(p=0.21). There were also no statistically significant differences between age groups for 
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the SF-6D (p=0.17), the EQ-5D (p=0.17) or the HUI-3 (p=0.26). For the SF-6D and the 
HUI-3, the lowest health utility values were measured for the oldest age group of patients 
that were greater than 75 years old. THA patients that were between the ages 65 years 
and 75 years of age reported the highest health utiity values as derived by the SF-6D and 
the EQ-5D. The highest health utility values across the three age-groups were found with 
the HUI-3. There were no significant differences in health utility values between the time 
since surgery intervals as measured by the SF-6D (p=0.19), the EQ-5D (p=0.32) or the 
HUI-3 (p=0.06). For all three generic, preference-based measures, the highest health 
utility values were found in the group of THA patients that were between two and five 
years from surgery at the time of the survey. The highest median health utility value was 
measured using the EQ-5D for THA patients between two and five years follow-up. The 
standard gamble approach was used to determine the health utilities for the SF-6D and 
the HUI-3. Because the standard gamble approach is dependent upon the level of one’s 
risk aversion, the health utilities are typically hig er when elicited using the standard 
gamble approach. In contrast, the time trade off method does not include risk of death as 
an alternative and it typically yields lower utility than those produced using SG 
methods.24,27 Therefore, it is unexpected to find higher health utility values as measured 
by the EQ-5D which used the time trade-off method to etermine the possible health 
utilities. 24,27 
Total Knee Arthroplasty 
Results of Univariate Analysis 
Sample Characteristics. Of the 987 individuals who participated in the online 
survey, 548 (55.7%) were TKA patients. Fifty-three percent (291 of 550) of the TKA 
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patients were female (Table 10) and the mean age of the TKA cohort was 65.3 years (SD 
8.28 years; Range 33.9 – 87.6 years). Nearly half of TKA patients were < 65 years old 
(270 of 550 (49.1%)), 211(38.4%) were between 65 years and 75 years old and only 69 
(12.5%) were over the age of 75 years (Table 13). At the time of the survey, the mean 
time since surgery (follow-up) was 2.89 years (SD 2.5 years) for the TKA cohort. Two 
hundred and sixty four (48%) of the TKA patients were less than two years from surgery 
at the time of the survey, 192 (34.9%) patients were between two years and five years 
from surgery and 94 (17.1%) were greater than five years from surgery at the time of the 
survey. 
The demographics of the TKA patients included in the study sample differed from 
the TKA patient population at OrthoCarolina. Knee patients at OC were significantly 
(p<0.0001) older than the knee patients included in the study. The mean age of the knee 
patients in the study sample was 65.3 years (SD 8.28 years) and the mean age for OC 
knee patient was 67.4 years (SD 10.63 years). There was also a lower proportion of 
patients in the study sample that were greater than 75 years of age (12.55%) than in the 
OC TKA patient population (23.43%). There was a greater proportion of female TKA 
patients at OC (61%) as compared to the knee patients included in the study (53%). These 
differences in age-group proportions (p<0.0001) and gender proportions (p=0.0007) were 
statistically significant.  
Disease Specific Measures. Out of a maximum score of 50 points, the mean KSS 
pain score was 40.8 points (SD 13.8 points; Range 0 – 5  points). In this cohort of TKA 
patients, the mean KSS function score was 83.1 (SD 20.6 points; Range 0 – 100 points) 
out of a maximum score of 100 points. The total WOMAC® score is a composite of the 
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function, pain and stiffness subscores. The mean WOMAC® stiffness score was 78.9 
points (SD 20.5 points; Range 12.5 – 100 points). The WOMAC® pain and function 
scores for the TKA cohort were similar. The mean pai  score was 87.7 points (SD 16.2 
points; Range 5 – 100 points) and the mean function sc re was 87 points (SD 16.6 points; 
Range 4.4 – 100 points). For the TKA patients, the mean total WOMAC® score was 85.8 
(SD 16.1; Range 9 – 100 points). The KOOS score includes subscores for activity of 
daily living function (FnADL), sports and recreation activity function (FnSRA), pain, 
quality of life (QOL), and knee symptoms. While theKOOS questionnaire includes the 
total WOMAC® score, there is no total KOOS score. TKA patients also rated themselves 
the lowest with respect to FnSRA (Mean 64.9 points; SD 27.5 points; Range 0 – 100 
points) and QOL (Mean 70.6 points; SD 24.3 points; Range 0 – 100 points). On average, 
the KOOS symptom subscore, pain subscore, and FnADL subscore were all between 81 
points and 87 points.  
Generic, Preference-based Measures. Table 11 illustrate  the median values for all 
three health utility measures. The health utility values derived from the SF-6D were 
slightly lower (Median 0.80 points) and a little more variable (IQR 0.24 points; Range 
0.4200 – 1.0000) on average than the values derived from the EQ-5D and HUI-3. A total 
of 506 (92%) TKA patients completed the EQ-5D. The m dian EQ-5D value was 0.83 
points (IQR 0.20 points; Range 0.3078 – 1.0000).  The highest median utility value for 
the TKA patients was the HUI-3.The median HUI-3 health utility value was 0.85 points 
(IQR 0.23; Range -0.19 – 1.00. Because the standard gamble approach is dependent upon 
the level of one’s risk preference, it is expected that the HUI-3 and SF-6D would yield 
higher utility than the EQ-5D which was developed using the TTO method.24,27  
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Results of Bivariate Analysis 
Sample Characteristics. A student T-test was used to determine differences 
between the mean disease specific scores for males and females.  Using a standard 
significance level of 5%, there were no significant differences between males and 
females in age at the time of the survey or years since surgery at the time of survey. Table 
12 illustrates the differences with respect to gender. There were statistically significant 
differences in pain and function levels between male and female TKA patients. Females 
reported significantly more pain and lower function levels as measured by the KSS, and 
the WOMAC®. Additionally, females reported significantly lower function and more pain 
on the relevant KOOS subscores as compared to male TKA patients. Using our threshold 
of 10 point difference in these scores as the clinically meaningful threshold, none of these 
differences were clinically meaningful. Analysis of variance tests were used to compare 
the mean values of the disease specific measures and the generic, preference-based 
measures with respect to the three age groups (Table 13) and three follow-up periods 
(Table 14). There were no statistically significant differences in KS pain scores (p=0.38) 
or KS function scores (p=0.07) between the three age groups. As measured by each 
domain of the WOMAC®, mean WOMAC® scores were nearly identical across all three 
age groups. There was a statistically significant (p=0.04) difference in the symptoms 
subscore across age groups. The youngest age group experienced more pain (Mean 78.8 
points, SD 17.5 points), on average, than patients over the age of 65 years at the time of 
the survey. In addition to age effects, patients whom are less than two years from surgery 
at the time of survey report higher postoperative pain levels and lower postoperative 
function levels as compared to those who are either between two and five years or greater 
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than five years from surgery. These differences were statistically significant for all 
subscores of the Knee Society, WOMAC®, and KOOS questionnaires. There was a 
clinically meaningful difference in WOMAC® stiffness subscore with those less than two 
years from surgery experiencing significantly more kn e stiffness. TKA patients less than 
two years from surgery also reported statistically nd clinically lower sports and 
recreation function levels as well as lower QOL compared to those with more time 
between the dates of surgery and survey. 
Generic, Preference-based Measures. There were significant differences between 
males and females in health utility values for the SF-6D and the EQ-5D. Male TKA 
patients reported a significantly (p=.0009) higher median SF-6D health utility of 0.84 
(IQR 0.20) compared to the median SF-6D value of 0.80 reported by female TKA 
patients. Similarly, the median EQ-5D health utility was 0.84 for males compared to .83 
for females (p=0.03). There were no statistically significant differences in health utility 
measures across age groups for either the SF-6D (p=0.37), EQ-5D (p=0.19), HUI-3 
(p=0.10). The lowest health utility measures for the TKA patients was 0.77 (IQR 0.18) as 
derived by the SF-6D. The highest health utility of 0.91 (IQR 0.22) was reported by the 
youngest TKA patients (less than 65 years) There wer  also no statistically significant 
differences across follow-up periods between the SF-6D (p=0.35), EQ-5D (p=0.34), or 
HUI-3 (p=0.44). Although not statistically significant, the highest health utility value was 
reported by TKA patients that were between two and five years from surgery at the time 
of the survey as derived using the HUI-3. Because standard gamble methods tend to yield 
higher utility values, it is expected that the health utilities derived from the SF-6D and 
HUI-3 will be higher on average than the values obtained using the EQ-5D.24,27 
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Results of Multivariate Analysis: Prediction Models 
A total of 60 prediction models were developed and tested for each combination 
of generic, preference based measure (health utility) and disease specific measure. The 
models are presented in Table 3. Eighty-five percent of the sample was used to develop 
the prediction models and 15% of the sample was used to test, or validate the models. 
Four criterion measures were used to evaluate the performance of the prediction models: 
mean error (ME), mean absolute (MAE), root mean square error (RMSE) and the 
percentage of errors greater than 0.1. The ME is the average forecast error, which is the 
difference between the estimated, or predicted, health utility value and the actual, 
observed, health utility value. The ME is used to assess the prediction models’ accuracy 
in estimating the health utility value at the group level because underestimated values and 
overestimated values cancel each other. The MAE is the average forecast error between 
the estimated health utility value and the actual he lt  utility value without regard to the 
direction, or sign, of the error. The RMSE is the square root of the mean of the squared 
forecast errors. The MAE and the RMSE are used to assess the ability of the model to 
accurately predict health utility values at the individual level. The percentage of errors 
greater than 0.1 was also used to assess the model’s pr cision in predicting the health 
utility value at the individual observation level. Because there is no guidance in the 
literature for an acceptable threshold, a value of 10% of the forecast error greater than 0.1 
was selected. Moreover, if 10%, or less of the forecast error was greater than 0.1, the 
model is deemed appropriate for use in estimating healt  utility values at the individual 
observation level. 
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A total of 30 THA models were developed and validate  to map each of the three 
hip disease specific measures (WOMAC®, HHS, HOOS) to each of the three healthy 
utility measures (SF-6D, EQ-5D, HUI-3). Similarly, 30 TKA models were developed and 
validated to map each of the three of knee disease specific measures (WOMAC®, KSS, 
KOOS) to each of the three healthy utility measures (SF-6D, EQ-5D, HUI-3). The ME 
for all of the 60 mapping models was nearly zero, with non-zero values only when one 
was willing to report out to 15 decimal places. The additional prediction performance 
measures (MAE, RMSE, and proportion of error over 0.1) for the THA regression models 
and neural networks are presented in Tables 15-21. Table 15 illustrates the forecast errors 
for the mapping of the WOMAC, the HHS, and the HOOS to the SF-6D. Similarly, the 
performance measures for 10 EQ-5D mapping models ar reported in Table 16 and the 10 
HUI-3 mapping models are reported in Table 17. The prediction measures for the TKA 
data are presented in the same manner in Tables 22-24. The best performing THA models 
and the recommendations for the most accurate mapping combinations as well as the best 
performing disease specific measure and generic preference-based measure are presented 
in Table 18. Table 25 reports the recommendations fr the top performing pairs and 
measures for the TKA sample. The coefficient estimates for the 9 most accurate THA 
prediction models are reported in Table 19 (SF-6D), Table 20 (EQ-5D) and Table 21 
(HUI-3). For the TKA cohort, the coefficient estimates of the 9 top performing models 
are presented in Tables 26-28. 
For each of the combinations, or pairs, of the healt  utility measures and disease 
specific measures one model was chosen as the most accurate prediction model. Of the 
30 THA models developed and tested for each of the 9 pairs, 9 models were selected as 
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the best performing models to predict each health utility from each THA disease specific 
measure. From those 9 prediction models, the overall best performing model to predict a 
health utility from a THA disease specific measure was selected. The validation models 
with the lowest forecasting errors were selected as the most accurate prediction model. 
While the validation dataset was used for decision making, the performance measures for 
the development, or analysis, dataset were also evaluated. The same selection process of 
the most accurate mapping models was used for the TKA sample. In every case, the 
models that included the WOMAC®, the HHS/KSS, or the HOOS/KOOS subscores as 
well as demographic data (age, gender, follow-up), interaction terms, and squared terms 
were selected as the best performing prediction models. Additionally, these best 
performing models had lower MAE and RMSE than each of t e corroborating neural 
networks. 
Total Hip Arthroplasty Mapping Models  
SF-6D Models. The performance criterion measures for the models mapping the 
SF-6D health utility value are reported in Table 15. Of the four models developed and 
validated to map the SF-6D to the WOMAC®, Model 4 was the most accurate. Model 4 
included the subscores of the WOMAC®, demographic factors and interaction terms. For 
the estimation sample, Model 2 had a lower percentage of large forecast errors, and the 
MAE and RMSE were lowest for Model 4. With respect to he validation dataset, or 
holdout sample, Model 4 had the lowest values for MAE and RMSE as well as the 
percentage of forecast errors greater than 0.1.  Because 26% of the forecast errors are 
greater than 0.1, Model 4 should only be used at the group level to predict the SF-6D 
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from the WOMAC®. If one only has WOMAC® scores, these data indicate that SF-6D is 
the preferred choice for mapping health utilities. 
Two models were developed for mapping the SF-6D and the Harris Hip Score. 
While only the pain and function subscores were avail ble for this study, the model that 
included the HHS subscores, demographic data, interaction terms and squared terms 
provided the lowest forecasting errors. For Model 6, 15% of the errors were greater than 
0.1. While the proportion of errors greater than 0.1 is lower as compared to Model 4, 
Model 6 is also not appropriate to estimate the SF-6D from the HHS at the individual 
level. However, this model is appropriate for use at the group level.   
For the mapping combination of SF-6D and HOOS, fourmodels were tested. 
Model 10 was selected as the most accurate of thesefour prediction models and it 
includes the factors of the HOOS subscores, demographic data, interaction terms and 
squared terms. Model 10 had the lowest values on all four criterion measures for the 
estimation sample. For the validation sample, the MAE, the RMSE and the percentage of 
large errors were all considerably lower for Model 10. Model 10 is appropriate for use at 
the group level. However, the proportion of errors greater than 0.1 is greater than the 10% 
threshold which indicates it may not accurately predict the SF-6D from the HOOS at the 
individual level. The coefficient estimates for the b st performing models developed to 
map the WOMAC®, the HHS, and the HOOS to the health utility derivd from the SF-6D 
are reported in Table 19. These coefficient estimates can be used by researchers to apply 
Model 4 (WOMAC®), Model 6 (HHS) and Model 10 (HOOS) to their datase s to 
estimate SF-6D health utilities. For example if one has access to HHS, then Model 6 is 
the appropriate model to use. 
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EQ-5D Models. The performance criterion measures for the models mapping the 
EQ-5D health utility values are reported in Table 16. There was some variability among 
the performance criterion measures for selecting the best performing WOMAC® mapping 
model. Models 3 and 4 were very close. Model 3 had t e lowest percentage of large 
errors while Model 4 had the lowest MAE and RMSE. Researchers could be confident 
using either model at the group level only. 
Model 6 (HHS) and Model 10 (HOOS) had similarly low forecast errors for the 
holdout sample. For both of these models, only 12% of the sample had forecast errors 
greater than 0.1. However, this is greater than the 10% criterion and thus Model 6 and 
Model 10 should be used to estimate EQ-5D health utility values at the group level. 
Given that a researcher only has access to HHS or HOOS data, the EQ-5D provides the 
best option for mapping health utility values. Table 20 illustrates the coefficient estimates 
for the most accurate models to predict the EQ-5D healt  utilities are presented. 
Depending on which disease specific measures are avilable, researchers can use the 
coefficient estimates from either Model 4, Model 6 or Model 10 to estimate health 
utilities derived from the EQ-5D from their respective THA cohorts.  
HUI-3 Models. The performance criteria measures for the models mapping the 
HUI-3 are presented in Table 17. Of the models mapping the WOMAC® to the HUI-3, 
Model 4 had the lowest MAE, RMSE and percentage of large errors for the holdout 
sample. For Model 4, a total of 30% of the errors were greater than .1 so this model 
should only be used to estimate the HUI-3 at the group level.  
Model 6 and Model 10 are again, the best performing models to predict the HUI-3 
from the HHS and the HOOS, respectively. The percentage of large errors was 18% for 
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Model 6 and 17% for Model 10. We would recommend that ese models were only used 
to estimate the HUI-3 at the group level. The models used to map the THA related 
disease specific measures to the HUI-3 yielded the highest forecast errors among all of 
the mapping pairs for the THA cohort. Therefore, we would not recommend using the 
HUI-3 for THA patients. With that recommendation in mind, the coefficient estimates for 
mapping the HUI-3 from either of the 3 disease specific measures are presented in Table 
21. 
Summary Total Hip Arthroplasty Models. 
The results from the data indicate that the single, best performing model for THA 
patients is Model 10 which mapped the HOOS to the EQ-5D. Using the holdout sample, 
the MAE was 0.0522 and the RMSE was 0.0649.  Only 12% of the forecast errors were 
above the threshold criterion of 0.1. It is important to note that Model 6 that mapped the 
HHS to the EQ-5D had very similar forecast errors. For Model 6, the MAE was 0.0551 
and the RMSE was 0.0705. Only 12% of the holdout sample for Model 6 had large 
errors, which is equivalent to proportion of large errors found using Model 10. With such 
small differences in the performance criterion values between Model 6 and Model 10 one 
could debate a tie for the best performing model for THA mapping pairs.  
 
Total Knee Arthroplasty Mapping Models.  
SF-6D Models. The performance criterion measures for the models mapping the 
WOMAC®, the KSS, and the KOOS to the SF-6D are illustrated in Table 22. Four 
models were developed and validated to map the WOMAC® to the SF-6D health utility. 
Of these four models, Model 4 had the lowest MAE and RMSE. As previously described, 
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Model 4 included factors for the WOMAC® subscores, demographic data, interaction 
terms and squared terms. Because 22% of the forecast rrors were greater than 0.1, the 
SF-6D and WOMAC® should only be mapped at the group level.  
Model 6 had the lowest forecast errors of the two models that mapped the KSS to 
the SF-6D. While the forecast errors indicate that Model 6 is also an acceptable mapping 
option, health utilities derived using the SF-6D should only be estimated at the group 
level. Model 10 had the lowest MAE, and RMSE values and was the most accurate of the 
four prediction models that mapped the KOOS to the SF-6D. Model 10 resulted in a total 
of 25% of the forecast errors above 0.1. Therefore, this model is also not appropriate to 
be used to estimate the SF-6D health utilities of individual TKA patient level.  
The forecast error values were all very similar among these three top performing 
SF-6D models. The MAE ranged from 0.0709 to 0.0750 and the RMSE ranged from 
.0876 to .0974.  These data suggest that these models can be used to map to the group 
level but we do not recommend that any of the SF-6D models be used to map at the 
individual TKA patient level. The coefficient estimates for Model 4, Model 6 and Model 
10 are reported in Table 26. Researchers can use the coefficient estimates to estimate 
the SF-6D health utility of their TKA cohort. 
EQ-5D Models. Table 23 reports the performance critrion measures of the 
models that map the WOMAC®, the KSS, and the KOOS to the health utilities derived 
from the EQ-5D. The forecast errors were very similar for the four models developed and 
tested to predict the EQ-5D from the WOMAC®. Model 3 had the lowest ME. However, 
Model 4 showed the lowest MAE and RMSE values and is deemed as the best 
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performing model. Only 10% of the errors noted in Model 4 were greater than 0.1 so it 
can confidently be applied at the individual patient l vel and the group level.  
Model 6 was clearly the best performing model to estimate the EQ-5D from the 
KSS. Model 6 had the lowest MAE and RMSE. Additionally, 12% of the errors were 
larger than 0.1, which indicates that it performs well at the the group level, only. Model 
10 showed the lowest MAE and RMSE values and was the most precise model in 
mapping the KOOS to the EQ-5D health utility. While only 13% of the errors were 
greater than 0.1, Model 6 can only be used to estimate the EQ-5D from the KSS at the 
group level. The coefficient estimate for the best performing models in mapping each of 
the three disease specific measures to the EQ-5D derive  health utilities are presented in 
Table 27. Researchers can apply these models using these coefficients to estimate the 
EQ-5D health utility of a group of TKA patients. Because the percentage of forecast 
errors are greater than 15%, we do not recommend applying any of these EQ-5D 
mapping models to individual TKA patients. 
HUI-3 Models. Table 24 reports the performance criteria measures for the models 
mapping to the HUI-3 health utility values. Of the t ree health utility measures, the HUI-
3 results in the highest forecast errors when mapped to ither the WOMAC®, the KSS or 
the KOOS. Nevertheless, the models that include the subscores, demographic data, 
interaction terms and squared terms were the most precise of the HUI-3 mapping models. 
This includes Model 4 for the WOMAC®, Model 6 for KSS and Model 10 for the KOOS. 
All of these models had more than 30% of the forecast errors greater than 0.1. Therefore, 
if one must estimate the health utility derived using the HUI-3 it should only be 
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undertaken at the group level. To apply any of these HUI-3 mapping models to another 
TKA dataset, one can use the coefficient estimates reported in Table 28. 
Summary Total Knee Arthroplasty Mapping Models. 
These results indicate that Model 6 produces the most accurate health utility 
values of all of the TKA mapping models. Model 6 maps the KSS to health utility values 
derived from the EQ-5D. For Model 6, the MAE was 0.051 and the RMSE was .064. 
However, the percentage of large errors was 10% for Model 4 compared to 12% for 
Model 6. Ultimately model 6 was favored because the ot r measures were slightly 
higher for Model 4. The MAE for Model 4 was 0.056 and the RMSE was 0.07.  
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DISCUSSION 
 
 
 The safety and efficacy of TJA is most commonly evaluated and reported in the 
literature using disease specific measures of healt-re ated quality of life.3,4,6,8,12,14,16-19  
To assess the outcomes of THA, disease specific measur s including the WOMAC®, the 
HHS and the HOOS are used. To assess clinical outcomes f TKA, the WOMAC®, the 
KSS and the KOOS are the most commonly reported disease-specific measures. While 
these tools provide meaningful data, these disease specific measures cannot directly be 
used in economic evaluations involving CUA. Best practices in cost-effectiveness 
analysis involve the use of quality adjusted life years as the outcome of interest in an 
intervention.  Researchers must have information on the patient’s level of health and the 
duration of time spent in that health state to calcul te QALY’s.  Multi-dimensional 
HRQOL questionnaires, such as the SF-6D, EQ-5D, and HUI-3, can be administered to 
obtain the health utility level. To date, these general, preference-based HRQOL 
instruments have not been routinely administered in an orthopedic practice setting.   
In order to meet the current and future demands of defining value-based medicine, 
or cost-effective treatments, researchers need the tools to conduct economic evaluations 
in a timely manner by utilizing data that are routinely collected on patients in an 
orthopedic setting. Therefore, we sought to generate regression models that could be used 
by researchers to accurately predict, or map to, a health utility from a common disease 
specific measure. To that end we conducted a multi-center, cross-sectional survey of total 
joint arthroplasty patients. Total hip patients completed the WOMAC®, HHS, and HOOS 
and total knee patients completed the WOMAC®, KSS, and KOOS. All patients 
completed the SF-6D, EQ-5D, and HUI-3 preference-based measures.  
43 
 
To our knowledge, there are no published studies that present utility values for 
relatively representative TKA or THA patient populations.  The health utility values 
reported in the literature for total hip replacement are very specific to intervention and 
limited by small sample sizes. Therefore, the healt utilities reported in this dissertation 
provide useful information for researchers who wish to use average values from the 
literature as model inputs for future cost-effectiveness model studies. The median health 
utility level for the total hip replacement cohort ranged from 0.86 (SF-6D) to 0.91 (HUI-
3). We found that these values remained consistent regardless of gender and the age-
group of THA patients. Similarly, we did not find any significant differences in utility 
values derived from any of the three indirect measures across the time intervals between 
surgery date and survey date for THA patients. For the TKA cohort, the health utility 
values were 0.80 (SF-6D), 0.83 (EQ-5D) and 0.85 (HUI-3). While we found statistically 
significant differences in the SF-6D and EQ-5D health utilities between male and female 
TKA patients, the differences are not clinically meaningful. Furthermore, the health 
utilities remained consistent across age groups and time intervals between date of surgery 
and date of survey.  
Considering that the EQ-5D yielded the most precise mapping models, we 
recommend that the EQ-5D health utility values repoted here are used by researchers. 
We posit that the EQ-5D was most accurately estimated by most of the disease-specific 
measures because the domains between these instrumen s ar  most closely related. The 
domains and subscales of the EQ-5D include mobility, self-care, usual activity, pain and 
discomfort, anxiety and depression. As compared to the SF-6D and HUI-3, a greater 
proportion of the EQ-5D questions relate to pain and function which are most relevant to 
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orthopedic conditions in general. More specifically, the TJA disease specific measures 
are also predominantly measuring pain and function.   
The purpose of the study was to develop and test regression models using 
multiple pairs of disease, specific measures and geeric, preference-based measures. A 
total of 30 THA mapping models and 30 TKA mapping models were developed and 
validated. Forecast errors including ME, MAE, RMSE and the percentage of errors 
greater than 0.1 were defined as our prediction performance criterion. The models that 
had the lowest forecast error measures on the validation dataset, or hold-out-sample, were 
selected as the best performing or most accurate prediction models. Furthermore, we 
posited that that a model should only be used to estimate health utilities at the individual 
observation level 10% or fewer of the observations from the hold-out-sample had forecast 
errors greater than 0.1.  
Grootendorst et al.39 were among the first researchers to develop a mapping 
model to predict a HUI-3 health utility from an OA disease specific measure, the 
WOMAC® in patients with OA of the knee. Marshall et al. sub equently repeated the 
Grootendorst et al.39 investigation, developing and testing four regression models to map 
the WOMAC® to the HUI-3 using a dataset of 145 patients with h p OA.40 The model 
that included the WOMAC® subscores, age, gender, OA duration, interaction terms and 
squared terms performed marginally better than the o r models. Marshall et al. reported 
a MAE of 0.1698, a RMSE of 0.1684 and a ME of 0.0120 for the most accurate model. 
Our findings are consistent with Marshall et al.40 We noted that our Model 4 was the 
most accurate mapping the WOMAC® and the HUI-3, with a MAE of 0.0901, a RMSE of 
0.1177 and a ME of 1.5231xE-15. The forecast error measures we reported are lower 
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than the forecast error measures reported by Marshall et al. Consistent with Marhsall et 
al., we also do not recommend that the model is used at the individual patient level.40 
While the model provides reasonably accurate health utility estimates, we found that all 
of the models that estimate the HUI-3 from any disease specific measure are associated 
with higher forecast error measures as compared to the SF-6D and the EQ-5D.  
Compared to the forecast errors from the Marshall et a . study, the forecast errors 
for the single best performing hip Model 10 in this study, which mapped the HOOS to the 
EQ-5D , were considerably lower. The MAE was 0.0522, the RMSE was 0.0649 and the 
ME was 2.381xE-16. Additionally, only 12% of the errors were greater than 0.1. 
Therefore, we confidently recommend that this model provides accurate estimates of EQ-
5D health utilities at the group level in the situations when direct elicitation of 
preferences is not possible.  
In a sample of 255 patients with OA of the knee, Grootendorst et al. developed 
and validated four prediction models to map the WOMAC® to the HUI-3.39 The best 
performing model in their study was the one that included the WOMAC® subscores, age, 
gender, years since OA onset, squared terms and interaction terms. This finding is 
consistent with the present study in that all of the best performing models included 
disease specific subscores, age, gender, time form su gery to survey, squared terms an 
interaction terms. Grootendorst et al. reported a MAE of 0.1628, a RMSE of 0.2065 and 
an ME of -0.0003.39 These forecast error measures are larger than those we have 
reported. The MAE for our Model 4 (WOMAC® and HUI-3) was 0.1067, the RMSE was 
0.1542 and the ME was 5.2775E-16. While Grootendorst et al. concluded that the model 
was appropriate for mapping at the group level, they do not recommended that 
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researchers use the model to estimate the health utili ies of individual patients.39 Because 
32.5% of the forecast errors were greater than 0.1, we also do not recommend that HUI-3 
utility values be estimated from the WOMAC® at the individual level. With respect to the 
HUI-3, the KOOS mapping is more accurate than the or disease specific measures. 
Nevertheless, the forecast errors of all of the HUI-3 models were the largest among the 
three preference-based measures. Therefore, we do not recommend using the HUI-3 
health utility with either TKA or THA cohorts.  
For the TKA cohort, Model 6, which mapped the KSS to the EQ-5D, provided the 
most accurate health utility estimates. For this model, the MAE was 0.051, the RMSE 
was .064 and the ME was 6.323E-16. In comparison, the forecast errors with the 
Grootendorst et al. hip OA mapping model, were substantially larger. Thus, we feel 
confident that researchers can apply this regression m del to their respective TKA group 
cohorts to estimate health utilities derived from mapping the HHS.  
Limitations 
 The cross sectional survey used to obtain data for the TTU mapping is subject to a 
number of internal validity threats. Because the qustions measure general constructs of 
pain, function, mobility and general health, the qustions across tools are similar. The 
presentation of one question may affect the answer on another question presented later. 
Therefore, testing and instrumentation threats to internal validity are concerns. To 
minimize these threats, random assignment to blocks defining different orders of 
questionnaires was done. Selection bias is also a concern. A sample of OrthoCarolina, 
P.A. patients with no emails in the patient registry was compared with the OrthoCarolina, 
P.A. study sample of those with email addresses. There was a significantly greater 
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proportion of females with no emails than men. On aver ge, patients with no emails were 
three years older than patients with email addresses. Therefore, the convenience sample 
of those who have email addresses may represent a healthier sample with higher levels of 
independence, cognitive ability, and functional ability. It is also possible that those who 
volunteer participation may elect to do so either bcause they are more or less satisfied 
with their health status compared to non-volunteers and may not be representative of the 
larger sample. There was a significantly higher propo tion of females that did not respond 
to the survey as compared to those that did respond. However, there were no differences 
between these two groups with respect to age or time s nce surgery.  
 External validity is also a limitation of this study. The sample is from two private 
orthopedic practices of high volume, specialty surgeons. We compared demographic 
variables between the study sample and the OrthoCarolin  TJA population to evaluate the 
extent to which the study sample is representative of a larger population. We found that 
significant differences did exist. In comparing thedemographic characteristics of the two 
knee samples, there was a significantly lower proportion of females in the study sample 
and the study sample was significantly younger thane OC population of TKA patients. 
These demographic differences were not as profound in the hip patients and the reason 
for this finding is unclear. Nevertheless, the results may not be generalizable to the 
populations of TKA and THA patients. Additionally, as noted in the literature review, 
due to the methodological challenges with TTU, predictive validity of the mapping 
models may be limited with the relatively narrow coverage of the disease specific 
measures relative to the broader, preference-based measures. The models developed may 
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require further research to larger arthroplasty populations to determine reliability and 
validity. 
Future Research 
 The results of this study highlight potential areas for future research. The 
accuracy of these linear regression equations may be improved by investigating other 
nonlinear regression models. A comparison of the for cast errors associated with the 
linear and nonlinear models would inform future researchers in this area to the most 
accurate models to use to estimate health utilities. Additionally, it may be useful to 
further investigate the precision of models in estima ing health utilities for various 
subpopulations, i.e males vs. females and different age-groups. One next logical step is to 
evaluate how the calculation of the incremental cost-effectiveness ratio varies using the 
estimated health utility compared to the actual heat  utility. It is also important for other 
researchers to use these regression equations on their datasets to test the robustness of the 
models in accurately predicting health utilities. Finally, this line of research can be 
extended into other subspecialties of orthopedic medicine. 
   
Summary 
 
In spite of the limitations noted, a total of five osteoarthritis disease specific 
measures commonly used to evaluate TJA were mapped to three commonly used 
preference-based health utility scores derived from multi-attribute health assessment 
instruments. While TTU has been used in other healt-re ated studies, the few studies 
relevant to TJA included relatively small sample size  and have only mapped the 
WOMAC® to the HUI-3. These models were developed and tested using data collected 
49 
 
from two large orthopedic practices, which provided the largest sample that has been 
used to date to develop TTU regression models.  For cost utility analysis evaluating THA 
intervention options, the HHS subscores most precisely estimated an EQ-5D health 
utility. Given one has HHS pain and function scores, we recommend that Model 6 be 
used to map to the EQ-5D and derive a health utility value either at the individual patient 
level or at the group level. If one only has access to WOMAC® scores, we recommend 
that Model 4 be used to estimate an SF-6D health uti ity. EQ-5D health utilities are also 
precisely predicted using Model 10 and HOOS subscores. In the event that one needs to 
estimate health utilities for TKA interventions, the models predicting EQ-5D health 
utilities, regardless of the disease specific measure, were the most precise. If one has 
access to all three of these disease specific measures, we recommend using Model 6 to 
map the KSS to the EQ-5D. The models developed in this dissertation will allow 
clinician-researchers to translate disease specific out ome scores to utilities, thus 
improving the ability of osteoarthritis researchers and policymakers to consider the cost-
effectiveness of osteoarthritis-related interventions relative to interventions for very 
different diseases and conditions.  TTU offers a useful method to estimate utilities from 
disease specific measures and facilitate economic evaluations of current and new TJA 
interventions to better understand the true societal b nefit of the interventions. 
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FIGURES 
 
 
Total Joint Implant A:  
Five years X  0.75 health utility =  3.75 QALYs 
 
Total Joint Implant B:  
Five years X  0.50 health utility =  2.5 QALYs 
 
1.25 QALYs gained with intervention A 
Incremental Cost Effective Ratio = Cost of Implant A – Cost of Implant B 
                   QALYs Implant A - QALYs Implant B
 
Figure 1. Cost-Effective Analysis Example 
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Health Condition 
(End Stage Osteoarthritis, Total Joint Arthroplasty - Preoperative and Postoperative 
status) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. International Classification of Functioning, Disability and Health (ICF): 
Conceptual Framework of Disability 
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Figure 3. Schematic of the Analytic Steps in the Mapping Process (Chuang & Whitehead,    
2012)46 
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Y = f(X) 
X = set of numeric inputs (age, gender, time since surgery, disease specific score, 
relevant subscales for disease specific score) 
w = weights 
Y = set of numeric outputs 
F() = unknown functional relationship between the inputs and the outputs 
 
          X            F()       Y 
 
 
 
 
 
 
 
 
 
 
Figure 4. General Neural Network Diagram 
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Figure 6. RMSE across all TKA mapping models
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TABLES 
 
Table 1. Subscales of the Disease Specific Measures and Preference-based Utility 
Measures 
 
Questionnaire       Subscale 
 
Disease Specific 
Knee Society Score (KSS)     Pain, Function 
 
Harris Hip Score (HHS)     Pain, Function 
 
Western Ontario and McMaster Universities  
Osteoarthritis Index (WOMAC®)    Pain, Mobility, Stiffness 
 
Hip Disability and Osteoarthritis Outcomes 
Score (HOOS)      Pain, Symptoms, Daily 
Activity Limitations, Sport 
and Recreation Activity 
Limitations, Quality of Life  
 
Knee Injury and Osteoarthritis Outcomes Score   
 
Generic, Prefence-Based 
EuroQOL 5D (EQ-5D) Mobility, Self-care, Usual 
Activity, Pain and 
Discomfort, Anxiety and 
Depression 
 
Health Utilities Index 3 (HUI3)    Vision, Hearing, Speech,  
       Ambulation, Dexterity,  
       Cognition, Pain, Emotion  
 
Short Form 6D (SF-6D) Role Physical, Bodily 
Pain,Vitality, Social 
Functioning, Role Emotional, 
Mental Health 
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Table 2. Questionnaire Ordered Blocks 
 
 
Total Hip Arthroplasty  Block 1 SF-12, HOOS, EQ-5D, HHS, HUI3 
 
Total Knee Arthroplasty  Block 1 SF-12, KOOS, EQ-5D, KSS, HUI3 
 
Total Hip Arthroplasty Block 2 EQ-5D, HOOS, HUI3, HHS, SF-12 
 
Total Knee Arthroplasty Block 2 EQ-5D, KOOS, HUI3, KSS, SF-12 
 
Total Hip Arthroplasty Block 3 HUI3, HOOS, SF-12, HHS, EQ-5D 
 
Total Knee Arthroplasty Block 3 HUI3, KOOS, SF-12, KSS, EQ-5D 
 
Total Hip Arthroplasty Block 4 SF-12, HHS, EQ-5D, HOOS, HUI3 
 
Total Knee Arthroplasty Block 4 SF-12, KSS, EQ-5D, KOOS, HUI3 
 
Total Hip Arthroplasty Block 5 EQ-5D, HHS, HUI3, HOOS, SF-12 
 
Total Knee Arthroplasty Block 5 EQ-5D, KSS, HUI3, KOOS, SF-12 
 
Total Hip Arthroplasty  Block 6 HUI3, HHS, SF-12, HOOS, EQ-5D 
 
Total Knee Arthroplasty  Block 6 HUI3, KSS, SF-12, KOOS, EQ-5D 
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Table 3. Completed Pairs of Disease-Specific and General, Preference-Based Measures 
  Hip Knee 
  HHS HOOS WOMAC® KSS KOOS WOMAC® 
EQ-5D 399 408 408 504 506 506 
HUI 3 397 397 397 497 497 497 
SF-6 404 410 410 505 505 505 
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Table 4. Transfer to Utility Regression Models 
 
WOMAC ® Regressed onto Utility 
 
1) Utility = β0 + β1total + β2age + β3gender + β4years + µ 
2) Utility = β0 + β1pain + β2mobility + β3stiffness + β4age + β5gender + β6years + µ 
3) Utility = β0 + β1total + β2age + β3gender + β4years + β5total*age + β6total*gender 
+ β7total*years + β8total
2 + β9age
2 + β10years
2 + µ 
4) Utility = β0 + β1pain + β2mobility + β3stiffness + β4age + β5gender + β6years + 
β7pain*age + β8pain*gender + β9pain*years + β10mobility*age + 
β11mobility*gender + β12mobility*years + β13stiffness*age + β14stiffness*gender 
+ β15stiffness*years + β16pain
2 + β17mobility
2
 + β18stiffness
2 + β19age
2 + β20years
2 
+ µ 
 
KSS/HHS Regressed onto Utility 
 
1) Utility = β0 + β1total + β2age + β3gender + β4years + µ 
2) Utility = β0 + β1pain + β2function + β3age + β4gender + β5years + µ 
3) Utility = β0 + β1total + β2age + β3gender + β4years + β5total*age + β6total*gender 
+ β7total*years + β8total
2 + β9age
2 + β10years
2 + µ 
4) Utility = β0 + β1pain + β2function + β3age + β4gender + β5years + β6pain*age + 
β7pain*gender + β8pain*years + β9function*age + β10function*gender + 
β11function*years + β12pain
2 + β13function
2
 + β14age
2 + β15years
2 + µ 
 
KOOS/HOOS Regressed onto Utility 
 
1) Utility = β0 + β1qualityoflife + β2age + β3gender + β4years + µ 
2) Utility = β0 + β1pain + β2ActivityDaily  + β3ActivitySport + β4symptoms + 
β5qualityoflife + β6age + β7gender + β8years + µ 
3) Utility = β0 + β1total + β2age + β3gender + β4years +β5total*age + β6total*gender 
+ β7total*years + β8total
2 + β9age
2 + β10years
2 + µ 
4) Utility = β0 + β1qualityoflife + β2age + β3gender + β4years + β5qualityoflife*age + 
β6qualityoflife*gender + β7qualityoflife*years + β8qualityoflife
2 + β9age
2 + 
β10years
2 + µ 
5) Utility = β0 + β1pain + β2ActivityDaily  + β3ActivitySport + β4symptoms + 
β5qualityoflife + β6age + β7gender + β8years + β9pain*age + β10pain*gender + 
β11qualityoflife*age + β12qualityoflife*gender + β13qualityoflife*years + 
β14pain*years + β15ActivityDaily*age + β16ActivityDaily*gender + 
β17ActivityDaily*years + β18ActivitySport*age + β19ActivitySport*gender + 
β20ActivitySport*years + β21symptoms*age + β22symptoms*gender + 
β23symptoms*years + β24pain
2 + β25ActivityDaily
2 + β26ActivitySport
2 + 
β27symptoms
2 + β28qualityoflife
2 + β29age
2 + β30years
2 + µ 
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Table 5. Frequency and Proportions of Demographic Caracteristics for THA Cohort 
  Hip (n=437) 
  Freq % 
Gender     
Female 213 48.74 
Male 224 51.26 
Follow-up Period     
< 2 years 181 41.42 
2 to 5 years 155 35.47 
> 5 years 101 23.11 
Age Group      
< 65 years 242 55.38 
65 to 75 years 147 33.64 
> 75 years 48 10.98 
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Table 6. Means and Standard Deviations for THA Cohort 
 
  Hip 
  N Mean SD 
Years Since 
Surgery at Time of 
Survey 435 3.66 3.63 
Age at Time of 
Survey 435 62.97 10.75 
SF-6D 419 0.6600* 0.26+ 
EQ-5D 408 0.7998* 0.20+ 
HUI-3 367 0.7536* 0.19+ 
HHS Pain 413 36.01 9.93 
HHS Function 414 40.14 8.14 
WOMAC 
Function 413 80.78 19.12 
WOMAC Pain 416 82.99 19.22 
WOMAC 
Stiffness 416 77.64 22.27 
WOMAC TOTAL 411 81.12 19.11 
HOOS FnADL 413 80.78 19.12 
HOOS FnSRA 413 69.2 26.19 
HOOS Pain 416 82.75 19.09 
HOOS QOL 411 72.84 23.36 
HOOS Symptoms 416 81.05 18.14 
 
* Median values are reported 
+ Interquartile range is reported 
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Table 7. Means and Standard Deviations for THA Cohort by Gender 
 
  Hip 
  Female Male pvalue 
Years Since 
Surgery at Time of 
Survey 3.48 (3.38) 3.83 (3.86) 0.316 
Age at Time of 
Survey 61.96 (11.99) 63.92 (9.35) 0.059 
SF-6D .8590 (.26)* .8170 (.26)* 0.874 
EQ-5D .8438 (.20)* .8438 (.21)* 0.836 
HUI-3 .9188 (.20)* .8629 (.19)* 0.21 
HHS Pain 36.54 (9.58) 35.50 (10.25) 0.285 
HSS Function 40.04 (7.84) 40.23 (8.43) 0.821 
WOMAC Function 82.10 (19.44) 79.54 (18.77) 0.174 
WOMAC Pain 83.84 (19.86) 82.18 (18.60) 0.379 
WOMAC Stiffness 78.02 (22.20) 77.29 (22.38) 0.739 
WOMAC TOTAL 82.11 (19.38) 80.18 (18.84) 0.306 
HOOS FnADL 82.10 (19.44) 79.54 (18.77) 0.174 
HOOS FnSRA 70.96 (26.18) 67.54 (64.00) 0.186 
HOOS Pain 84.16 (19.30) 81.41 (18.83) 0.142 
HOOS QOL 74.81 (23.95) 70.95 (22.67) 0.094 
HOOS Symptoms 81.67 (18.13) 80.45 (18.18) 0.491 
 
*  Median value and interquartile range reported  
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Table 8. Means and Standard Deviations for THA Cohort by Age Group 
 
  Hip 
  < 65 years 65 to 75 years > 75 years   
  Mean (SD) Mean (SD) Mean (SD) Pvalue 
SF-6D .8170 (.26)* .8590 (.22)* .8085 (.22)* 0.17 
EQ-5D 0.8438 (0.22)* 0.8603 (0.19)* 0.8540 (0.19)* 0.17 
HUI-3 0.9054 (0.22)* 0.9047 (0.17)* 0.8543(0.36)* 0.26 
HHS Pain 34.29 (10.83) 37.94 (7.92) 38.62 (9.35) <0.00 1 
HHS Function 39.82 (8.73) 41.03 (6.34) 38.86 (9.86) 0.21 
HHS 
Modified 
Total 81.40 (19.78) 86.99 (13.09) 85.45 (17.64) 0.01 
WOMAC 
Function 79.52 (21.30) 81.62 (17.54) 84.71 (17.34) 0.21 
WOMAC 
Pain 80.96 (20.92) 84.76 (17.02) 87.84 (15.23) 0.04 
WOMAC 
Stiffness 75.38 (23.48) 79.55 (20.58) 83.24 (19.80) 0.05 
WOMAC 
TOTAL 79.34 (20.50) 82.48 (17.25) 86.07 (16.21) 0.06 
HOOS 
FnADL 79.52 (20.30) 81.62 (17.54) 84.71 (17.34) 0.21 
HOOS 
FnSRA 67.54 (26.98) 70.38 (24.22) 74.13 (27.94) 0.26 
HOOS Pain 80.50 (20.98) 84.81 (16.19) 87.78 (15.84) 0.02 
HOOS QOL 68.50 (25.37) 76.95 (18.54) 82.27 (21.64) <0.0001 
HOOS 
Symptoms 78.78 (19.96) 83.29 (15.29) 85.57 (15.03) 0.01 
 
*  Median value and interquartile range reported   
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Table 9. Means and Standard Deviations for THA Cohort by Time Since Surgery 
 
  Hip 
  < 2 years 2 to 5 years > 5 years   
  Mean (SD) Mean (SD) Mean (SD) Pvalue 
SF-6D 0.8170 (0.26)* 0.8590 (0.24)* 0.8085 (0.26)* 0.19 
EQ-5D 0.8435 (0.21)* 1.000 (0.20)* 0.8438 (0.20)* 0.32 
HUI-3 0.8543 (0.22)* 0.9188 (0.17)* 0.8543 (0.22)* 0.06 
HHS Pain 34.45 (10.29) 37.08 (9.66) 37.18 (9.37) 0.03 
HHS 
Function 38.99 (8.73) 41.06 (7.93) 40.78 (7.10) 0.05 
HHS 
Modified 
Total 80.85 (18.60) 85.88 (17.34) 85.75 (15.85) 0.02 
WOMAC 
Function 78.55 (19.74) 82.79 (18.58) 81.65 (18.62) 0.13 
WOMAC 
Pain 81.10 (19.71) 84.25 (18.88) 84.44 (18.75) 0.24 
WOMAC 
Stiffness 74.13 (22.88) 80.48 (21.92) 79.60 (21.04) 0.02 
WOMAC 
TOTAL 78.70 (19.58) 83.11 (18.78) 82.39 (18.50) 0.09 
HOOS 
FnADL 78.55 (19.74) 82.79 (18.58) 81.65 (18.62) 0.13 
HOOS 
FnSRA 64.68 (27.18) 73.80 (24.27) 70.15 (26.16) 0.01 
HOOS Pain 80.76 (19.58) 84.25 (18.74) 84.03 (18.60) 0.2 
HOOS QOL 69.71 (23.42) 75.78 (24.46) 73.90 (21.02) 0.06 
HOOS 
Symptoms 79.39 (18.43) 82.64 (18.48) 81.58 (17.01) 0.27 
 
*  Median value and interquartile range reported 
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Table 10. Frequency and Proportions of Demographic C aracteristics for TKA Cohort 
 
  Knee (n=550) 
  Freq % 
Gender     
Female 291 52.91 
Male 259 47.09 
Follow-up 
Period     
< 2 years 264 48 
2 to 5 years 192 34.91 
> 5 years 94 17.09 
Age Group      
< 65 years 270 49.09 
65 to 75 years 211 38.36 
> 75 years 69 12.55 
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Table 11. Means and Standard Deviations for TKA Cohort  
 
  Knee 
  N Mean SD 
Years Since Surgery at 
Time of Survey 548 2.89 2.5 
Age at Time of Survey 548 65.3 8.28 
SF-6D 521 0.6810* 0.24+ 
EQ-5D 506 0.7998* 0.20+ 
HUI-3 460 0.7056* 0.23+ 
KSS Pain 515 40.83 13.81 
KSS Function 513 83.13 20.61 
WOMAC Function 509 87.04 16.58 
WOMAC Pain 517 87.73 16.2 
WOMAC Stiffness 521 78.89 20.46 
WOMAC TOTAL 509 85.76 16.07 
KOOS FnADL 509 87.04 16.58 
KOOS FnSRA 509 64.91 27.5 
KOOS Pain 517 85.91 17.11 
KOOS QOL 509 70.65 24.3 
KOOS Symptoms 521 80.72 16.87 
 
* Median value is reported 
+ Interquartile range is reported 
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Table 12. Means and Standard Deviations for TKA Cohort by Gender 
 
  Knee 
  Female Male pvalue 
Years Since 
Surgery at Time 
of Survey 3.05 (2.70) 2.71 (2.25) 0.1044 
Age at Time of 
Survey 64.89 (8.61) 65.76 (7.89) 0.2205 
SF-6D .79660 (0.18)* .8380 (0.20) * 0.009 
EQ-5D .8271 (.21)* .8438 (.18)* 0.025 
HUI-3 .8543 (.22)* .8794 (.22)* 0.270 
KSS Pain 39.20 (14.50) 42.68 (12.76) 0.0039 
KSS Function 79.17 (21.38) 87.59 (18.75) <.0001 
WOMAC 
Function 85.80 (17.26) 88.44 (15.71) 0.0729 
WOMAC Pain 85.95 (17.37) 89.71 (14.56) 0.0077 
WOMAC 
Stiffness 76.77 (21.80) 81.25 (18.62) 0.0118 
WOMAC TOTAL 84.20 (16.86) 87.51 (14.98) 0.0205 
KOOS FnADL 85.80 (17.26) 88.44 (15.71) 0.0729 
KOOS FnSRA 61.69 (28.44) 68.52 (25.99) 0.0051 
KOOS Pain 84.47 (18.09) 87.51 (15.83) 0.0422 
KOOS QOL 69.49 (24.57) 71.95 (23.99) 0.2548 
KOOS Symptoms 79.83 (17.56) 81.72 (16.05) 0.2019 
 
*  Median value and interquartile range reported  
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Table 13. Means and Standard Deviations for TKA Cohort by Age Group 
 
  Knee 
  < 65 years 65 to 75 years > 75 years   
  Mean (SD) Mean (SD) Mean (SD) pvalue 
SF-6D .8000 (.25)* .8000 (.20)* .7680 (.1189)* 0.37 
EQ-5D 0.8271 (0.20)* 0.8438 (0.18)* 0.8271 (0.22)* 0.19 
HUI-3 0.9054 (0.22)* 0.8543 (0.19)* 0.8004 (.29)* 0.10 
KSS Pain 40.12 (14.34) 41.12 (13.45) 42.74 (12.66) 0.38 
KSS 
Function 84.26 (21.14) 83.43 (19.25) 77.58 (22.06) 0.07 
WOMAC 
Function 87.21 (16.95) 87.19 (15.69) 85.90 (18.04) 0.84 
WOMAC 
Pain 87.56 (17.08) 88.20 (14.76) 86.92 (17.13) 0.84 
WOMAC 
Stiffness 78.62 (20.72) 79.86 (19.67) 76.89 (21.95) 0.57 
WOMAC 
TOTAL 85.72 (16.61) 86.16 (15.12) 84.66 (17.04) 0.81 
KOOS 
FnADL 87.21 (16.95) 87.19 (15.69) 85.90 (18.04) 0.84 
KOOS 
FnSRA 64.21 (27.43) 65.68 (26.42) 65.24 (31.26) 0.85 
KOOS Pain 85.23 (18.06) 86.67 (15.81) 86.20 (17.35) 0.66 
KOOS QOL 68.75 (24.76) 72.46 (23.54) 72.42 (24.71) 0.23 
KOOS 
Symptoms 78.85 (17.51) 82.04 (16.15) 83.82 (15.95) 0.04 
 
* Median value and interquartile range is reported 
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Table 14. Means and Standard Deviations for TKA Cohort by Time Since Surgery 
 
  Knee 
  < 2 years 2 to 5 years > 5 years   
Variable Mean (SD) Mean (SD) Mean (SD) Pvalue 
SF-6D 0.8000 (0.24)* 0.8000 (0.23)* 0.7910 (0.21)* 0.35 
EQ-5D 0.8271 (0.22)* 0.8438 (0.18)* 0.8271 (0.20)* 0.34 
HUI-3 0.8458 (0.25)* 0.8794 (0.21)* 0.8668 (0.17)* 0.44 
KSS Pain 38.61 (15.06) 42.87 (11.83) 42.92 (12.99) 0.002 
KSS Function 80.65 (22.11) 85.82 (19.21) 84.72 (18.12) 0.03 
WOMAC 
Function 84.07 (17.44) 89.48 (15.75) 90.30 (14.42) 0.0005 
WOMAC Pain 85.43 (17.03) 89.72 (15.04) 90.06 (15.39) 0.0081 
WOMAC 
Stiffness 73.65 (20.97) 83.10 (18.24) 84.86 (19.87) <0.0001 
WOMAC 
TOTAL 82.61 (16.76) 88.48 (14.68) 88.97 (15.32) 0.00 1 
KOOS FnADL 84.07 (17.44) 89.48 (15.75) 90.30 (14.42) 0.0005 
KOOS FnSRA 61.46 (28.22) 65.93 (26.93) 72.30 (25.19) 0.005 
KOOS Pain 82.64 (18.49) 88.80 (14.98) 89.07 (15.64) 0.0002 
KOOS QOL 65.79 (25.28) 74.22 (23.05) 76.83 (21.47) <0.0001 
KOOS 
Symptoms 76.65 (17.60) 84.52 (14.40) 84.33 (16.99) <0.0001 
 
* Median value and interquartile range is reported 
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Table 15. Comparison of Predictive Performance Criteria for the SF-6D and the THA 
Cohort 
  n MAE 
Error 
>.1 RMSE 
Estimation Sample         
Model 1- WOMAC Total Score 346 0.1040 43.4% 0.1248 
Model 2 - WOMAC Subscores 346 0.1011 38.8% 0.1229 
Model 3 - WOMAC Total Score 
& Interactions 346 0.0999 43.1% 0.1210 
Model 4 - WOMAC Subscores & 
Interactions 346 0.0957 40.2% 0.1173 
Neural Network WOMAC 
Subscores 346 0.1045   0.1245 
Model 5 - Harris Hip Score 341 0.0838 28.3% 0.1052 
Model 6 - Harris Hip Score & 
Interactions 341 0.0822 27.5% 0.1040 
Neural Network Harris Hip Score 341 0.0838   0.1052 
Model 7 - HOOS QOL 347 0.0991 38.8% 0.1205 
Model 8 - HOOS QOL & 
Interactions 347 0.0952 37.2% 0.1163 
Model 9 - HOOS Subscores 345 0.0958 36.9% 0.1173 
Model 10 - HOOS Subscores & 
Interactions 345 0.0899 34.5% 0.1114 
Neural Nework HOOS Subscores 345 0.0944   0.1177 
Holdout Sample         
Model 1- WOMAC Total Score 65 0.0923 37.9% 0.1136 
Model 2 - WOMAC Subscores 65 0.0934 36.4% 0.1123 
Model 3 - WOMAC Total Score 
& Interactions 65 0.0840 30.3% 0.1025 
Model 4 - WOMAC Subscores & 
Interactions 65 0.0742 25.8% 0.0912 
Neural Network WOMAC 
Subscores 65 0.0971   0.1179 
Model 5 - Harris Hip Score 62 0.0667 22.7% 0.0826 
Model 6 - Harris Hip Score & 
Interactions 62 0.0574 15.2% 0.0711 
Neural Network Harris Hip Score 62 0.0720   0.0878 
Model 7 - HOOS QOL 64 0.0849 27.3% 0.1009 
Model 8 - HOOS QOL & 
Interactions 64 0.0733 30.3% 0.0893 
Model 9 - HOOS Subscores 64 0.0949 45.5% 0.1096 
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Table 15 (continued)      
      
Model 10 - HOOS Subscores & 
Interactions 64 3.1398E-16 0.0561 19.7% 0.0724 
Neural Network HOOS 
Subscores 64   0.0851   0.1040 
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Table 16. Comparison of Predictive Performance Criteria for the EQ-5D and the THA 
Cohort 
  N MAE 
Error > 
.1 RMSE 
Estimation Sample         
Model 1- WOMAC Total 
Score 342 0.10622 34.0% 0.13738 
Model 2 - WOMAC Subscores 342 0.1049 34.2% 0.1361 
Model 3 - WOMAC Total 
Score & Interactions 342 0.1058 35.8% 0.1306 
Model 4 - WOMAC Subscores 
& Interactions 342 0.1030 38.8% 0.1267 
Neural Network WOMAC 
Subscores 342 0.1071   0.1374 
Model 5 - Harris Hip Score 337 0.0797 25.9% 0.1025 
Model 6 - Harris Hip Score & 
Interactions 337 0.0797 24.5% 0.0993 
Neural Network Harris Hip 
Score 337 0.0883   0.1199 
Model 7 - HOOS QOL 344 0.0971 34.5% 0.1301 
Model 8 - HOOS QOL & 
Interactions 342 0.0974 32.6% 0.1241 
Model 9 - HOOS Subscores 342 0.0948 33.7% 0.1249 
Model 10 - HOOS Subscores 
& Interactions 342 0.0903 27.5% 0.1137 
Neural Network HOOS 
Subscores 342 0.1017   0.1350 
Holdout Sample 
Model 1- WOMAC Total 
Score 64 0.0907 30.3% 0.11279 
Model 2 - WOMAC Subscores 64 0.08671 33.3% 0.11021 
Model 3 - WOMAC Total 
Score & Interactions 64 0.0828 25.8% 0.10337 
Model 4 - WOMAC Subscores 
& Interactions 64 0.0750 27.3% 0.09558 
Neural Network WOMAC 
Subscores 64 0.0950   0.11537 
Model 5 - Harris Hip Score 62 0.0659 16.7% 0.0817 
Model 6 - Harris Hip Score & 
Interactions 62 0.0551 12.1% 0.0705 
Neural Network Harris Hip 
Score 62 0.0653   0.0818 
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Table 16 (continued)     
Model 7 - HOOS QOL 64 0.0668 24.2% 0.0906 
Model 8 - HOOS QOL & 
Interactions 64 0.0654 18.2% 0.0833 
Model 9 - HOOS Subscores 64 0.0622 16.7% 0.0842 
Model 10 - HOOS Subscores 
& Interactions 64 0.0522 12.1% 0.0649 
Neural Network HOOS 
Subscores 64 0.0756   0.0954 
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Table 17. Comparison of Predictive Performance Criteria for the HUI-3 and the THA 
Cohort 
  n MAE 
Error > 
.1 RMSE 
Estimation Sample         
Model 1- WOMAC Total Score 308 0.13146 36.9% 0.18554 
Model 2 - WOMAC Subscores 308 0.1290 38.5% 0.1826 
Model 3 - WOMAC Total Score 
& Interactions 308 0.1249 40.2% 0.1747 
Model 4 - WOMAC Subscores & 
Interactions 308 0.1216 39.4% 0.1676 
Neural Network WOMAC 
Subscores 308 0.1333   0.1851 
Model 5 - Harris Hip Score 304 0.0929 25.9% 0.1375 
Model 6 - Harris Hip Score & 
Interactions 304 0.0896 24.3% 0.1333 
Neural Network Harris Hip Score 304 0.1114   0.1606 
Model 7 - HOOS QOL 310 0.12672 40.2% 0.17933 
Model 8 - HOOS QOL & 
Interactions 310 0.1211 36.1% 0.1692 
Model 9 - HOOS Subscores 308 0.1244 38.5% 0.1751 
Model 10 - HOOS Subscores & 
Interactions 308 0.1133 35.3% 0.1577 
Neural Network HOOS 
Subscores 308 0.1312   0.1818 
Holdout Sample 
Model 1- WOMAC Total Score 57 0.1244 43.9% 0.1608 
Model 2 - WOMAC Subscores 57 0.1217 45.5% 0.1583 
Model 3 - WOMAC Total Score 
& Interactions 57 0.1001 33.3% 0.1309 
Model 4 - WOMAC Subscores & 
Interactions 57 0.0901 30.3% 0.1177 
Neural Network WOMAC 
Subscores 57 0.1260   0.1634 
Model 5 - Harris Hip Score 57 0.0990 27.3% 0.1370 
Model 6 - Harris Hip Score & 
Interactions 57 0.0747 18.2% 0.0994 
Neural Network Harris Hip Score 55 0.0990   0.1364 
Model 7 - HOOS QOL 57 0.10728 34.8% 0.14088 
Model 8 - HOOS QOL & 
Interactions 57 0.0833 30.3% 0.1162 
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Table 17 (continued)     
Model 9 - HOOS Subscores 57 0.1023 33.3% 0.1388 
Model 10 - HOOS Subscores & 
Interactions 57 0.0657 16.7% 0.0938 
Neural Network HOOS 
Subscores 57 0.1137   0.1547 
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Table 18. Best Performing THA Models and Recommendations for Mapping Pairs 
 
  SF-6D EQ-5D HUI-3 
Preferred 
Utility 
Measure 
WOMAC 
Model 4 
Group 
only 
Model 4 
Group 
only 
Model 4 
Group 
only SF-6D 
Harris Hip  
Model 6 
Individual 
& Group 
Model 6 
Individual 
& Group 
Model 6 
Group 
only EQ-5D 
HOOS 
Model 10 
Group 
only 
Model 10 
Individual 
& Group 
Model 
10 
Group 
only EQ-5D 
Preferred Disease 
Specific 
Harris 
Hip 
Harris 
Hip / 
HOOS 
Harris 
Hip / 
HOOS   
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Table 19. Coefficient Estimates for Best Performing Models Estimating SF-6D 
WOMAC 
Model 4 
Variable 
WOMAC 
Model 4 
Coefficient 
Estimate 
Harris Hip 
Model 6  
Variable 
Harris Hip 
Model 6 
Coefficient 
Estimate 
HOOS 
Model 10  
Variable 
HOOS 
Model 10 
Coefficient 
Estimate 
R2 0.3053 R2 0.4545 R2 0.3729 
Intercept -0.34484 Intercept 0.06275 Intercept -0.07232 
Pain 0.01604^ HHS Pain 0.01039 FnDL -0.00587 
Function 
-0.0095 
HHS Function 
0.00454 
FnSRA 
0.00354 
Stiffness 0.00694^ Age 0.00664 Pain 0.00943 
Age 0.01633^ Gender -0.04104 QOL 0.00589^ 
Gender -0.10882 Followup 0.0005755 Symptoms -0.0001377 
Followup 0.00061898 Pain * Age -0.0001564 Age 0.01053 
Pain * Age 
-0.00016158 Pain * 
Followup 
0.0001366 
Gender 
-0.09771 
Pain * 
Gender 
0.00129 
Pain * Gender 
0.00146 
Followup 
0.00537 
Pain * 
Followup 
0.00006254 
Function*Age 
6.96E-06 
Pain * Age 
-0.0000738 
Function * 
Age 
0.0001744 Function * 
Followup 
-0.000165 Pain * 
Gender 
0.0016 
Function * 
Gender 
-0.00015343 Function * 
Gender 
-0.0005784 Pain * 
Followup 
0.0003259 
Function * 
Followup 
-0.00007699 
Pain * Pain 
1.684E-05 
Pain * Pain 
-0.0000452 
Stiffness * 
Age 
-
0.00012813^ 
Function * 
Function 
6.477E-05 FnDL * 
Age 
0.0000677 
Stiffness * 
Gender 
0.00009293 
Age * Age 
-6.23E-06 FnDL * 
Gender 
0.0009557 
Stiffness * 
Followup 
0.00001421 Followup * 
Followup -7.31E-06 
FnDL * 
Followup 
-0.0005052 
Pain * Pain 
-0.00004944 
    
FnDL * 
FnDL 
0.0000272 
Function * 
Function 
0.00002386 
    
FnSRA * 
Age 
-0.0000128 
Stiffness * 
Stiffness 7.86E-07     
FnSRA * 
Gender -0.0008074 
Age * Age 
-0.00005283   
  
FnSRA * 
Followup 
0.0001330 
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Table 19 (continued)    
 
Followup * 
Followup -0.00006199     
FnSRA * 
FnSRA 
-0.0000168 
        QOL * Age -0.0000918 
        
QOL * 
Gender 
0.0008835 
        
QOL * 
Followup 
-0.0000258 
        
QOL * 
QOL 
0.00000898 
        
Symptoms 
* Age 
0.0000156 
        
Symptoms 
* Gender 
-0.00157 
        
Symptoms 
* Followup 
0.0000391 
        
Symptoms 
* 
Symptoms 
-0.0000018 
        Age * Age -0.0000329 
        
Followup * 
Followup -0.0001578 
 
^ Statistical significance p < .05 
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Table 20. Coefficient Estimates for Best Performing Models Estimating EQ-5D 
WOMAC 
Model 4 
Variable 
WOMAC 
Model 4 
Coefficient 
Estimate 
Harris Hip 
Model 6  
Variable 
Harris Hip 
Model 6 
Coefficient 
Estimate 
HOOS 
Model 10  
Variable 
HOOS 
Model 10 
Coefficient 
Estimate 
R2 .3789 R2 .6181 R2 .4999 
Intercept -0.51514 Intercept 0.15452 Intercept -0.09453 
Pain 0.01374 HHS Pain 0.01692^ FnDL 0.00382 
Function 0.00227 HHS Function 0.00927 FnSRA 0.00149 
Stiffness 0.00248 Age -0.000251 Pain 0.01166 
Age 0.01778^ Gender -0.046 QOL 0.00662 
Gender -0.15935^ Followup -0.00673 Symptoms -0.007 
Followup 0.00644 Pain * Age -0.000116 Age 0.00924 
Pain * Age 
-
0.00007262 
Pain * 
Followup 
-0.000221 
Gender 
-0.0975 
Pain * 
Gender 
0.00491^ 
Pain * Gender 
0.00404^ 
Followup 
-0.00038357 
Pain * 
Followup 
0.00034801 
Function*Age 
8.199E-05 
Pain * Age 
-0.0000803 
Function * 
Age 
0.00000524 Function * 
Followup 
0.0003064 Pain * 
Gender 
0.004 
Function * 
Gender 
-0.00434 Function * 
Gender 
-0.00271 Pain * 
Followup 
0.00064539 
Function * 
Followup 
-
0.00064623 Pain * Pain 
-8.99E-05 
Pain * Pain -0.00005836 
Stiffness * 
Age 
-
0.00005096 
Function * 
Function 
-6.54E-05 
FnDL * Age 
-0.00007325 
Stiffness * 
Gender 
0.00121 
Age * Age 
0.000011 
FnDL * 
Gender 
-0.00411 
Stiffness * 
Followup 
0.00024734 Followup * 
Followup 0.0001277 
FnDL * 
Followup 
-0.00102 
Pain * Pain 
-
0.00007335     
FnDL * 
FnDL 
0.0000386 
Function * 
Function 
0.00003213 
    
FnSRA * 
Age 
-0.00001707 
Stiffness * 
Stiffness 
-
0.00001225     
FnSRA * 
Gender 0.00094022 
Age * Age 
-
0.00006463 
  
  
FnSRA * 
Followup 
0.00009245 
Followup * 
Followup 
-
0.00013706     
FnSRA * 
FnSRA 
-0.00000731 
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Table 20 (continued)  
        QOL * Age -0.00002745 
        
QOL * 
Gender 
-0.00058718 
        
QOL * 
Followup 
-0.00010118 
        
QOL * 
QOL 
-0.00001583 
        
Symptoms * 
Age 
0.00016249 
        
Symptoms * 
Gender 
0.00093174 
        
Symptoms * 
Followup 
0.00040434 
        
Symptoms * 
Symptoms 
-0.00003168 
        Age * Age -0.00006077 
        
Followup * 
Followup -0.00021263 
 
^ Statistical significance p < .05 
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Table 21. Coefficient Estimates for Best Performing Models Estimating HUI-3 
WOMAC 
Model 4 
Variable 
WOMAC 
Model 4 
Coefficient 
Estimate 
Harris Hip 
Model 6  
Variable 
Harris Hip 
Model 6 
Coefficient 
Estimate 
HOOS 
Model 10  
Variable 
HOOS 
Model 10 
Coefficient 
Estimate 
R2 .3596 R2 .5855 R2 .4327 
Intercept -0.69489 Intercept -0.16269 Intercept -0.43747 
Pain 0.03542^ HHS Pain 0.02558^ FnDL -0.02289^ 
Function 
-0.01266 HHS 
Function 
0.01874 
FnSRA 
0.00742 
Stiffness 0.00591 Age -0.0009344 Pain 0.02693^ 
Age 0.01285 Gender -0.01153 QOL 0.00731 
Gender -0.04806 Followup -0.01324 Symptoms 0.01095 
Followup -0.01865 Pain * Age -0.0002025 Age 0.0079 
Pain * Age 
-0.00023851 Pain * 
Followup 
0.0005105 
Gender 
-0.0706 
Pain * 
Gender 
-0.00297 
Pain * Gender 
-0.00282 
Followup 
-0.01951 
Pain * 
Followup 
-0.00022107 
Function*Age 0.00011522 
Pain * 
Age 
-0.000298 
Function * 
Age 
0.00025384 Function * 
Followup 
-0.0002155 Pain * 
Gender 
-0.00159 
Function * 
Gender 
-0.00009856 Function * 
Gender 
0.00167 Pain * 
Followup 
-4.36E-05 
Function * 
Followup 
0.00025739 
Pain * Pain 
-0.0001594 Pain * 
Pain 
-5.07E-05 
Stiffness * 
Age 
-0.00016855 Function * 
Function 
-0.0001527 FnDL * 
Age 
0.0003783^ 
Stiffness * 
Gender 
0.0033 
Age * Age 
0.00000996 FnDL * 
Gender 
0.00128 
Stiffness * 
Followup 
0.00020134 Followup * 
Followup 0.00005754 
FnDL * 
Followup 
0.0001057 
Pain * Pain 
-0.00012567 
    
FnDL * 
FnDL 
9.99E-07 
Function * 
Function 
0.00001196 
    
FnSRA * 
Age 
-5.23E-05 
Stiffness * 
Stiffness 
0.00000758 
    
FnSRA * 
Gender -0.000582 
Age * Age 
-0.00002089   
  
FnSRA * 
Followup 
-0.000193 
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Table 21 (continued) 
Followup * 
Followup -0.00003164     
FnSRA * 
FnSRA 
-2.63E-05 
        
QOL * 
Age 
-2.82E-05 
        
QOL * 
Gender 
-0.00234 
        
QOL * 
Followup 
0.0002797 
        
QOL * 
QOL 
-2.16E-05 
        
Symptoms 
* Age 
-0.000117 
        
Symptoms 
* Gender 
0.00322 
        
Symptoms 
* 
Followup 
0.0001116 
        
Symptoms 
* 
Symptoms 
-3.53E-05 
        
Age * 
Age 
-1.71E-05 
        
Followup 
* 
Followup -0.000234 
 
^ Statistical significance p < .05 
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Table 22. Comparison of Predictive Performance Criteria for the SF-6D and the TKA 
Cohort 
  n MAE Error > .1 RMSE 
Estimation Sample         
Model 1- WOMAC Total Score 430 0.0915 37.7% 0.1075 
Model 2 - WOMAC Subscores 430 0.0890 34.5% 0.1053 
Model 3 - WOMAC Total 
Score & Interactions 430 0.0902 37.9% 0.1065 
Model 4 - WOMAC Subscores 
& Interactions 430 0.0865 33.6% 0.1032 
Neural Network WOMAC 
Subscores 430 0.0895   0.1060 
Model 5 - Knee Society 
Subscore 429 0.0873 33.2% 0.1046 
Model 6 - Knee Society 
Subscore & Interactions 429 0.0863 33.0% 0.1038 
Neural Network Knee Society 
Subscore 429 0.0877   0.1049 
Model 7 - KOOS QOL 430 0.0927 38.5% 0.1105 
Model 8 - KOOS QOL & 
Interactions 430 0.0912 35.5% 0.1088 
Model 9 - KOOS Subscores 430 .0877 33.2% 0.1043 
Model 10 - KOOS Subscores & 
Interactions 430 0.0836 32.8% 0.0997 
Neural Network KOOS 
Subscores 430 0.0857   0.1027 
Holdout Sample         
Model 1- WOMAC Total Score 76 0.0893 28.9% 0.1135 
Model 2 - WOMAC Subscores 76 0.0883 31.3% 0.1109 
Model 3 - WOMAC Total 
Score & Interactions 76 0.0851 28.9% 0.1110 
Model 4 - WOMAC Subscores 
& Interactions 76 0.0750 21.7% 0.0974 
Neural Network WOMAC 
Subscores 76 0.0857   0.1085 
Model 5 - Knee Society 
Subscore 77 0.0781 28.9% 
0.0945 
Model 6 - Knee Society 
Subscore & Interactions 77 0.0709 19.3% 0.0876 
Neural Network Knee Society 
Subscore 77 0.0801   0.0946 
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Table 22 (continued)     
Model 7 - KOOS QOL 76 0.0865 30.1% 0.1142 
Model 8 - KOOS QOL & 
Interactions 76 0.0866 26.5% 0.1113 
Model 9 - KOOS Subscores 76 0.0863 31.3% 0.1084 
Model 10 - KOOS Subscores & 
Interactions 76 0.0735 25.3% 0.0936 
Neural Network KOOS 
Subscores 76 0.0859   0.1110 
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Table 23. Comparison of Predictive Performance Criteria for the EQ-5D and the TKA 
Cohort  
  n MAE 
Error 
> .1 RMSE 
Estimation Sample         
Model 1- WOMAC Total Score 430 0.0847 28.9% 0.1087 
Model 2 - WOMAC Subscores 430 0.0847 25.5% 0.1064 
Model 3 - WOMAC Total Score & 
Interactions 430 0.0829 25.5% 0.1060 
Model 4 - WOMAC Subscores & 
Interactions 430 0.0810 23.1% 0.1025 
Neural Network WOMAC 
Subscores 430 0.0852   0.1070 
Model 5 - Knee Society Subscore 428 0.0816 27.2% 0.1030 
Model 6 - Knee Society Subscore 
& Interactions 428 0.0812 25.3% 0.1020 
Neural Network Knee Society 
Subscore 428 0.0806   0.1105 
Model 7 - KOOS QOL 430 0.0879 31.5% 0.1169 
Model 8 - KOOS QOL & 
Interactions 430 0.0884 29.3% 0.1130 
Model 9 - KOOS Subscores 430 0.0834 25.5% 0.1060 
Model 10 - KOOS Subscores & 
Interactions 430 0.0790 25.5% 0.1008 
Neural Network KOOS Subscores 430 .0834   0.1053 
Holdout Sample 
Model 1- WOMAC Total Score 76 0.0712 19.3% 0.0837 
Model 2 - WOMAC Subscores 76 0.0677 13.3% 0.0792 
Model 3 - WOMAC Total Score & 
Interactions 76 0.0702 15.7% 0.0827 
Model 4 - WOMAC Subscores & 
Interactions 76 0.0554 9.6% 0.0703 
Neural Network WOMAC 
Subscores 76 0.0754   0.0847 
Model 5 - Knee Society Subscore 76 0.0576 15.7% 0.0690 
Model 6 - Knee Society Subscore 
& Interactions 76 0.0505 12.0% 0.0639 
Neural Network Knee Society 
Subscore 76 0.0591   0.0737 
Model 7 - KOOS QOL 76 0.0640 16.9% 0.0820 
Model 8 - KOOS QOL & 
Interactions 76 0.0644 18.1% 0.0800 
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Table 23 (continued)     
Model 9 - KOOS Subscores 76 0.0643 18.1% 0.0777 
Model 10 - KOOS Subscores & 
Interactions 76 0.0511 13.3% 0.0671 
Neural Network KOOS Subscores 76 0.0762   0.0858 
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Table 24. Comparison of Predictive Performance Criteria for the HUI-3 and the TKA 
Cohort 
Estimation Sample n MAE 
Error > 
.1 RMSE 
Model 1- WOMAC Total Score 389 0.1157 38.1% 0.1520 
Model 2 - WOMAC Subscores 389 0.1134 37.5% 0.1511 
Model 3 - WOMAC Total Score 
& Interactions 389 0.1142 36.2% 0.1505 
Model 4 - WOMAC Subscores 
& Interactions 389 0.1086 33.8% 0.1465 
Neural Network WOMAC 
Subscores 389 0.1074   0.1449 
Model 5 - Knee Society 
Subscore 389 0.1050 30.2% 0.1420 
Model 6 - Knee Society 
Subscore & Interactions 389 0.1028 30.6% 0.1386 
Neural Network Knee Society 
Subscore 389 0.1047   0.1408 
Model 7 - KOOS QOL 389 0.1185 37.5% 0.1560 
Model 8 - KOOS QOL & 
Interactions 389 0.1158 36.2% 0.1531 
Model 9 - KOOS Subscores 389 0.1108 34.0% 0.1496 
Model 10 - KOOS Subscores & 
Interactions 389 0.1061 31.3% 0.1439 
Neural Network KOOS 
Subscores 389 0.1041   0.1397 
Holdout Sample         
Model 1- WOMAC Total Score 71 0.1351 42.2% 0.1853 
Model 2 - WOMAC Subscores 71 0.1256 42.2% 0.1750 
Model 3 - WOMAC Total Score 
& Interactions 71 0.1349 48.2% 0.1769 
Model 4 - WOMAC Subscores 
& Interactions 71 0.1067 32.5% 0.1542 
Neural Network WOMAC 
Subscores 71 0.1280   0.1819 
Model 5 - Knee Society 
Subscore 71 0.1236 37.3% 0.1765 
Model 6 - Knee Society 
Subscore & Interactions 71 0.1119 34.9% 0.1558 
Neural Network Knee Society 
Subscore 71 0.1191   0.1767 
Model 7 - KOOS QOL 71 0.1375 41.0% 0.1926 
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Table 24 (continued)     
Model 8 - KOOS QOL & 
Interactions 71 0.1359 43.4% 0.1851 
Model 9 - KOOS Subscores 71 0.1253 34.9% 0.1750 
Model 10 - KOOS Subscores & 
Interactions 71 0.0989 34.9% 0.1387 
Neural Network KOOS 
Subscores 71 0.1283   0.1868 
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Table 25. Best Performing TKA Models and Recommendations for Mapping Pairs  
 
  SF-6D EQ-5D HUI-3 
Preferred 
Utility 
Measure 
WOMAC 
Model 4 
Group 
only 
Model 4 
Individual 
& Group 
Model 4 
Group 
only EQ-5D 
Harris Hip  
Model 6 
Group 
Only 
Model 6 
Individual 
& Group 
Model 6 
Group 
only EQ-5D 
HOOS 
Model 10 
Group 
only 
Model 10 
Individual 
& Group 
Model 
10 
Group 
only EQ-5D 
Preferred 
Disease 
Specific 
Knee 
Society 
All Very 
Close 
All Very 
Close   
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Table 26. Coefficient Estimates for Best Performing  Models Estimating SF-6D 
WOMAC 
Model 4 
Variable 
WOMAC 
Model 4 
Coefficient 
Estimate 
Knee 
Society 
Model 6  
Variable 
Knee Society 
Model 6 
Coefficient 
Estimate 
KOOS 
Model 10  
Variable 
KOOS 
Model 10 
Coefficient 
Estimate 
R2 .3502 R2 .3458 R2 .3937 
Intercept 0.24165 Intercept 0.75456 Intercept 0.72149 
Pain -0.00985 KS Pain 0.00156 FnDL -0.0019 
Function 
0.0096 
KS 
Function 
0.00139 
FnSRA 
0.0046 
Stiffness 0.00352 Age -0.00783 Pain -0.01397 
Age 0.00448 Gender -0.00765 QOL 0.00652 
Gender 0.02829 Followup 0.0093 Symptoms 0.01069^ 
Followup 
0.01829 
Pain * 
Age 
0.0000021 
Age 
-0.00905 
Pain * Age 
0.00009899 Pain * 
Followup 
-0.000225 
Gender 
-0.00685 
Pain * 
Gender 
0.00053116 
Pain * 
Gender 
0.00122 
Followup 
0.02229 
Pain * 
Followup 
0.00024302 
Function * 
Age 
0.00000599 
Pain * 
Age 
8.498E-05 
Function * 
Age 
-0.00005461 Function * 
Followup 
-3.735E-05 Pain * 
Followup 
0.00153^ 
Function * 
Gender 
-0.00058954 Function * 
Gender 
-0.0005275 Pain * 
Gender 
0.0007748 
Function * 
Followup 
-0.00053807 Pain * 
Pain 
0.00000395 Pain * 
Pain 
3.366E-05 
Stiffness * 
Age 
-0.00008981 Function * 
Function 
0.00001039 FnDL * 
Age 
0.0001522 
Stiffness * 
Gender 
-0.00005338 
Age * Age 
0.00005873 
FnDL * 
Gender 
-0.00197 
Stiffness * 
Followup 
-0.00000716 
Followup 
* 
Followup 
0.00013034 FnDL * 
Followup 
-0.000812^ 
Pain * Pain 
0.00001275 
    
FnDL * 
FnDL 
-6.99E-06 
Function * 
Function 
0.00000628 
    
FnSRA * 
Age 
-6.1E-05 
Stiffness * 
Stiffness 0.00001569     
FnSRA * 
Gender 
-0.000632 
Age * Age 
-0.0000076   
  
FnSRA * 
Followup 
0.0002105 
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Followup * 
Followup 0.00043385     
FnSRA * 
FnSRA 
-2.14E-06 
        
QOL * 
Age 
-0.000107^ 
        
QOL * 
Gender 
0.0007698 
        
QOL * 
Followup 
-0.000389^ 
        
QOL * 
QOL 
9.98E-06 
        
Symptoms 
* Age 
-0.000116 
        
Symptoms 
* Gender 
0.0005989 
        
Symptoms 
* 
Followup 
-0.000158 
        
Symptoms 
* 
Symptoms 
-1.78E-05 
        
Age * 
Age 
7.226E-05 
        
Followup 
* 
Followup 0.0004987 
 
^ Statistical significance p < .05 
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Table 27. Coefficient Estimates for Best Performing  Models Estimating EQ-5D 
WOMAC 
Model 4 
Variable 
WOMAC 
Model 4 
Coefficient 
Estimate 
Knee 
Society 
Model 6  
Variable 
Knee 
Society 
Model 6 
Coefficient 
Estimate 
KOOS 
Model 10  
Variable 
KOOS 
Model 10 
Coefficient 
Estimate 
R2 .5050 R2 .5021 R2 .5238 
Intercept -0.69812 Intercept 1.55973 Intercept -0.38483 
Pain -0.01315 KS Pain^ -0.00163 FnDL 0.01855^ 
Function 
0.03007^ 
KS 
Function 
-0.00412 
FnSRA 
0.00391 
Stiffness -0.00251 Age -0.02275 Pain -0.0165^ 
Age 0.01786^ Gender -0.14146 QOL 0.00322 
Gender 0.10322 Followup 0.01842 Symptoms 0.00784 
Followup 
0.00417 
Pain * 
Age 
-4.253E-05 
Age 
0.00963 
Pain * Age 
0.00015205 Pain * 
Followup 
-9.226E-05 
Gender 
0.08534 
Pain * 
Gender 
-0.00103 
Pain * 
Gender 
0.00117 
Followup 
-0.01693 
Pain * 
Followup 
-0.00031612 
Function 
* Age 
0.00013491 
Pain * 
Age 
0.0001742 
Function * 
Age 
-
0.00027657^ 
Function 
* 
Followup 
-0.0002163 Pain * 
Followup 
-0.00091 
Function * 
Gender 
-0.00008981 Function 
* Gender 
0.00076288 Pain * 
Gender 
4.796E-05 
Function * 
Followup 
-0.00008639 Pain * 
Pain 0.00012672 
Pain * 
Pain 
3.612E-05 
Stiffness * 
Age 
-0.00001243 
Function 
* 
Function 
-1.105E-05 FnDL * 
Age 
-0.000129 
Stiffness * 
Gender 
0.00009724 Age * 
Age 
0.0001089 FnDL * 
Gender 
-0.00142 
Stiffness * 
Followup 
0.00019987 
Followup 
* 
Followup 0.00051714 
FnDL * 
Followup 
6.292E-05 
Pain * Pain 
0.00003086 
    
FnDL * 
FnDL 
-3.06E-05 
Function * 
Function 
-
0.00003795^     
FnSRA * 
Age 
-6.91E-05 
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Table 27 (continued)     
Stiffness * 
Stiffness 0.00001942     
FnSRA * 
Gender -0.000489 
Age * Age 
-0.0000373   
  
FnSRA * 
Followup 
0.0002924 
Followup * 
Followup 0.00106     
FnSRA * 
FnSRA 
-1.91E-06 
        
QOL * 
Age 
-0.000257 
        
QOL * 
Gender 
-0.00128 
        
QOL * 
Followup 
0.0003846 
        
QOL * 
QOL 
1.659E-05 
        
Symptoms 
* Age 
0.0002285 
        
Symptoms 
* Gender 
0.00327 
        
Symptoms 
* 
Followup 0.0004765 
        
Symptoms 
* 
Symptoms 
-6.59E-05 
        Age * Age 5.329E-05 
        
Followup 
* 
Followup -0.00326^ 
 
^ Statistical significance p < .05 
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Table 28. Coefficient Estimates for Best Performing Models Estimating HUI-3 
WOMAC 
Model 4 
Variable 
WOMAC 
Model 4 
Coefficient 
Estimate 
Knee 
Society 
Model 6  
Variable 
Knee 
Society 
Model 6 
Coefficient 
Estimate 
KOOS 
Model 10  
Variable 
KOOS 
Model 10 
Coefficient 
Estimate 
R2 .3225 R2 .3932 R2 .3459 
Intercept -1.08313 Intercept -0.31597 Intercept -0.80949 
Pain -0.00262 KS Pain 0.02329 FnDL 0.0141 
Function 
0.01787 
KS 
Function 
-0.0007454 
FnSRA 
0.00089262 
Stiffness -0.00464 Age 0.02247^ Pain -0.00825 
Age 0.03646^ Gender -0.34406 QOL 0.00912 
Gender 0.13007 Followup -0.01135 Symptoms -0.00268 
Followup -0.02687 Pain * Age -0.00005973 Age 0.03087^ 
Pain * 
Age 
0.00006775 
Pain * 
Followup 
0.00247^ 
Gender 
0.0687 
Pain * 
Gender 
-0.00271 
Pain * 
Gender 
-0.00811 
Followup 
-0.05002^ 
Pain * 
Followup 
-0.00038595 
Function * 
Age 
0.00015118 
Pain * 
Age 0.00015231 
Function 
* Age 
-0.00023242 Function * 
Followup 
-0.00141^ Pain * 
Followup 
-0.0026 
Function 
* Gender 
0.00331 Function * 
Gender 
0.00772 Pain * 
Gender 
0.00003069 
Function 
* 
Followup 
0.00007207 
Pain * Pain 
-0.00029971 Pain * 
Pain 
-0.00001626 
Stiffness 
* Age 
0.00006185 Function * 
Function 
-0.00002504 FnDL * 
Age 
-0.00020313 
Stiffness 
* Gender 
-0.00223 
Age * Age 
-0.0002583^ FnDL * 
Gender 
0.00164 
Stiffness 
* 
Followup 
0.00051683 Followup * 
Followup 0.00266 
FnDL * 
Followup 
0.00058007 
Pain * 
Pain 
-0.00000312 
    
FnDL * 
FnDL 
0.00001528 
Function 
* 
Function 
0.00001668 
    
FnSRA * 
Age 
0.00002924 
Stiffness 
* 
Stiffness 0.00000111     
FnSRA * 
Gender -0.00093486 
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Table 28 (continued)   
 
Age * 
Age 
-0.00021262   
  
FnSRA * 
Followup 
-0.00047149 
Followup 
* 
Followup 0.00051208     
FnSRA * 
FnSRA 
-0.00000183 
        
QOL * 
Age 
-0.00013392 
        
QOL * 
Gender 
-0.00033242 
        
QOL * 
Followup 
0.00036461 
        
QOL * 
QOL 
8.53E-07 
        
Symptoms 
* Age 
0.00005089 
        
Symptoms 
* Gender 
0.00124 
        
Symptoms 
* 
Followup 
-0.00011033 
        
Symptoms 
* 
Symptoms 
-0.00000957 
        Age * Age 
-
0.00017994^ 
        
Followup 
* 
Followup 0.00018633 
 
^ Statistical significance p < .05 
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APPENDIX A: INTRODUCTORY SCREEN FOR ONLINE SURVEY 
 
Dear [total joint replacement patient], 
You are receiving this email because you have had a total [hip/knee] replacement surgery 
by [physician name] of the OrthoCarolina, P.A. Hip and Knee Surgeons. Dr [physician 
name] is collaborating with researchers at the University of North Carolina at Charlotte to 
determine accurate measures of health related quality of life for patients after surgery.  
 
Several questionnaires have been used for decades to evaluate health related quality of 
life or health outcomes, i.e. pain and function, after total joint replacement surgery. While 
these questionnaires are very useful in evaluating health outcomes following total joint 
replacement surgery, there are other questionnaires that provide another type of health 
related quality of life measure called health utility. Health utility measures are necessary 
for the calculations used to determine the cost-effectiveness of various osteoarthritis 
treatments including total joint replacement surgery.  
 
We are doing this study to develop calculations that can be used to determine the health 
utility scores based on the traditional pain and functional scores for patients who have 
had a joint replacement.  Results from this study ma  help researchers in the future 
conduct cost-effectiveness analyses of total joint replacement procedures. 
 
There are no foreseeable risks to participating in this study. The results of the study do 
not include any data that could be used to identify you. There are no direct benefits to you 
for participating in this study but the results may help others in the future. Your 
participation is voluntary and you have the choice to not participate. If you choose not to 
participate, there will be no loss of benefits to you and you may withdraw participation at 
any time without loss of benefits. 
 
If you volunteer to participate, you will spend approximately 30 minutes completing 
these questionnaires. If you agree to participate, please click next. You will then be asked 
to log in to complete the questionnaires. If you are not able to complete all of the 
questions in one sitting, you may take a break and come back at a later time to complete 
the remaining questions. We do hope you can complete th m in one day. 
 
If you have any questions about this study, please contact Susan Odum at 704-323-2265.  
 
Thank you, 
Susan Odum, MEd 
University of North Carolina at Charlotte; Doctoral Student, Health Services Research 
OrthoCarolina, P.A. Research Institute 
 
Jennifer Troyer, PhD 
University of North Carolina at Charlotte; Associate Professor, Economics 
 
Dr. [physician name] 
OrthoCarolina, P.A. Hip and Knee Center 
